

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A RETROSPECTIVE COHORT STUDY IN ETHIOPIA

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015743
Article Type:	Research
Date Submitted by the Author:	28-Dec-2016
Complete List of Authors:	Berhe, Derbew Fikadu; University of Groningen, University Medical Center Groningen, Clinical Pharmacology and Pharmacy; Mekelle University, School of Pharmacy Taxis, Katja; University of Groningen, Department of pharmacy, PharmacoTherapy, -Epidemiology and -Economics Haaijer-Ruskamp, Flora; University of Groningen, University Medical Center, Department of Clinical Pharmacy and Pharmacology Mulugeta, Afework; Mekelle University, School of Public Health Mengistu, Yewondwossen Tadesse; Addis Ababa University, College of Health Sciences, School of Medicine, Department of Internal Medicine Mol, Peter; University Medical Center Groningen, University Medical Center, Department of Clinical Pharmacy and Pharmacology
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics
Keywords:	Hypertension < CARDIOLOGY, Adult cardiology < CARDIOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

1  
2  
3 **HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY**  
4  
5 **PATIENTS: A RETROSPECTIVE COHORT STUDY IN EHTIOPIA**  
6

7 **Short title: hypertension treatment practices and determinants**  
8  
9

10  
11  
12 Derbew Fikadu Berhe<sup>1, 2</sup>, Katja Taxis<sup>3</sup>, Flora M Haaijer-Ruskamp<sup>1</sup>, Afework Mulugeta<sup>4</sup>, Yewondwossen  
13  
14 Tadesse Mengistu<sup>5</sup>, Peter GM Mol<sup>1</sup>  
15

16  
17 <sup>1</sup>Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical  
18  
19 Center Groningen, The Netherlands  
20

21  
22 <sup>2</sup>School of Pharmacy, College of Health Sciences, Mekelle University, Ethiopia  
23

24  
25 <sup>3</sup>Department of Pharmacy, Unit Pharmacotherapy, -epidemiology & economics, University of  
26  
27 Groningen, The Netherlands  
28

29  
30 <sup>4</sup>School of Public Health, College of Health Sciences, Mekelle University, Ethiopia  
31

32  
33 <sup>5</sup>Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa  
34  
35 University, Ethiopia  
36  
37

38 Corresponding author:  
39

40 Peter GM Mol  
41  
42 University Medical Center Groningen, UMCG  
43  
44 Department of Clinical Pharmacy and Pharmacology, EB70  
45  
46 Hanzeplein 1, PO BOX 30001, 9700 RB Groningen  
47  
48 The Netherlands  
49  
50 + 31 (0)50 363 8313, Fax. +31 (0)50 363 2812  
51  
52 Email: p.g.m.mol@umcg.nl  
53

54 Word count: 2,813,  
55

56 Number of tables: 3, supplement tables: 3, and, Figure: 1  
57

58 References: 31  
59  
60

**ABSTRACT**

**Objectives:** We examined determinants for achieving blood pressure control in hypertensive patients and for treatment intensification in patients with uncontrolled blood pressure.

**Design:** A retrospective cohort study in six public hospitals, Ethiopia

**Participants:** Adult ambulatory hypertensive patients with at least one previous prescribed antihypertensive medication.

**Outcome:** Controlled BP (<140/90 mm Hg), and treatment intensification for patients with uncontrolled BP.

**Results:** The study population comprised 897 patients. Their mean age was 57 (SD 14) years, 63% were females, and 35% had one or more cardiometabolic comorbidities mainly diabetes mellitus. BP was controlled in 37% patients. Treatment was intensified for 23% patients with uncontrolled BP. In multivariable (logistic regression) analysis, determinants positively associated with controlled BP were treatment at general hospitals (OR 1.89 [95% CI: 1.26; 2.83]) compared to specialized hospitals, and longer treatment duration (OR 1.04 [95% CI: 1.01; 1.06]). Negatively associated determinants were previously uncontrolled BP (OR 0.30 [95% CI: 0.21; 0.43]), treatment regimens with diuretics (OR 0.68 [95% CI, 0.50; 0.94]), and age (OR 0.99 [95% CI: 0.98; 1.00]). The only significant – positive - determinant for treatment intensification was duration of therapy (OR 1.05 [95% CI: 1.02; 1.09]).

**Conclusions:** The level of controlled BP and treatment intensification practice in this study was low. Intervention programs to improve BP control should target in particular specialized hospitals, and older patients. Treatment intensification should be initiated earlier.

**Key words:** hypertension, antihypertensive medication, blood pressure control, treatment intensification, ambulatory patients, Ethiopia, hospital, observational study

**STRENGTH AND LIMITATIONS**

- This is the first study which gives insight in determinants for hypertension treatment practice (level of BP control and treatment intensification) in a diverse population treated in public hospitals in Ethiopia.
- We analysed BP measurements as recorded in patients' medical records which reflected actual clinical practice, but may be subject to recording and measurement error.
- The finding of this study may not be generalizable to other settings such as private practice, primary health care centers in Ethiopia.

## BACKGROUND

Hypertension is a major risk factor for cardiovascular diseases, the leading cause of death and disability globally.[1] The World Health Organization (WHO) recently reported that 80% of deaths due to cardiovascular disease occur in low- and middle-income countries, with the highest death rate reported in African countries. The report also indicated that prevalence of hypertension in adults was highest in the African region (46%) compared to e.g. 35% in the region of the Americas.[1] Hypertension is more prevalent even among the African-origin population living in Western world than among whites.[2] The population of African ancestry is characterized by high vascular contractility, extreme salt sensitivity, and low renin release.[3-5] Hence, over-activation of the sympathetic nervous system and renin-angiotensin-aldosterone system is more prevalent in this population, making them more vulnerable to high blood pressure. In addition, changes in environmental factors such as economic development, urbanization, and lifestyle have resulted in an epidemiological transition from infectious to non-communicable disease such as hypertension in the African region.[6]

Large clinical outcome studies have repeatedly shown that treating hypertension improves cardiovascular outcomes.[7] However, to achieve target blood pressure (BP) using evidence based antihypertensive treatment and by adjusting life style remains a challenge in clinical practice. The majority of studies in Africa have shown that less than a third of patients achieves treatment goals.[8] Generally, four main factors for achieving BP control have been identified. First, there are factors intrinsic to the nature of the disease; in most cases hypertension is initially asymptomatic and this delays early prevention, diagnosis and treatment.[9] Second, poor treatment response may be due to patient-related factors such as age, gender, race, and compliance to medication.[4,10] Third, there are healthcare system-related factors such as lack of effective hypertension prevention and treatment programs, and access to medications. Fourth, prescriber behavior, competences, and large

1  
2  
3 patient-to-prescriber ratio affect hypertension prevention and treatment outcomes. The majority of  
4  
5 these factors have been extensively studied in western society; however, little is known of their  
6  
7 impact on BP control in developing nations. Some of these factors may be unique to, or more  
8  
9 pronounced in the African setting including low societal awareness, priority to fight infectious  
10  
11 diseases, and human resource limitations in particular the number of available healthcare  
12  
13 professionals.[6,11]  
14

15  
16  
17 Effective prevention and treatment strategies have been evaluated in the western world to  
18  
19 optimize BP control.[12] Such programs may be relevant for the African setting. However, to guide  
20  
21 targeted interventions studies identifying factors contributing to poor BP control in the African  
22  
23 setting are urgently needed. Studies conducted to date in Ethiopia, the second largest populous  
24  
25 country (approximately 100 million) in Africa, focused on determining prevalence of the disease.[13-  
26  
27 15] Although, prevalence was relatively low (10 – 30%),[1,13-15] further data on hypertension  
28  
29 treatment practices beyond mere drug utilization are lacking.[16] Therefore, we aimed to assess the  
30  
31 proportion of patients treated for hypertension who had controlled BP and identify determinants for  
32  
33 achieving BP control. In addition, we aimed to study whether treatment was intensified in those  
34  
35 patients with uncontrolled BP and identify the determinants for treatment intensification.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Study design and setting

This retrospective cohort study was conducted in outpatient clinics of six public hospitals in Addis Ababa (capital city) and Tigray regional state, Ethiopia. We included two specialized hospitals (Addis Ababa), and four general hospitals, three from Tigray and one from Addis Ababa.

### Study population

Participants were approached while waiting for their appointment in the waiting area of the outpatient clinics. They were recruited consecutively after giving consent. Hypertensive patients aged 18 years or above were included, if they had at least one previous antihypertensive medication prescription in the same hospital, and gave informed consent. Patients were identified based on patient report or marked on their pocket-size appointment card (for being hypertensive). These inclusion criteria were verified in each clinic log-book (if available), and individual patient medical record.

Routine practice in the study hospitals was that nurses measured patient's blood pressure, and assigned the patient to a physician. The physician will then consult the patient, confirm the diagnosis and if necessary perform further examinations including rechecking BP, and renew or amend prescribed medication. Patients will then collect their medicine from pharmacy outlets at the same hospital or if not available from private or community pharmacies.

### Data collection

Included patients were interviewed in the waiting area to collect data on their socio demographics, treatment duration of antihypertensive medication(s), and medication adherence. Clinical information including BP measurements, medication prescribed, and comorbid illnesses were retrieved from medical records for the current visit (*index visit*) and the previous visit (*prior visit*).



1  
2  
3 Data were collected by professional nurses or pharmacists who were trained in using a dedicated  
4  
5 case-report form. Data were collected between February and August, 2015.  
6

## 7 8 **Variables**

### 9 10 Outcome measures

11  
12 We defined two *outcome measures*. First, for *BP control* we used the 'standard' definition of  
13  
14 controlled BP, i.e., systolic BP/diastolic BP below 140/90 mm Hg at the index visit.[12] Second, we  
15  
16 defined *treatment intensification* as an increase in dose of an antihypertensive drug and/or addition  
17  
18 of one or more antihypertensive drug(s). Treatment intensification was calculated for those patients  
19  
20 who had a complete medication history (including dose and administration frequency) at both visits  
21  
22 and whose BP was not controlled at the index visit. A switch in drug class was not considered as  
23  
24 treatment intensification.  
25  
26  
27

### 28 29 Explanatory variables

30  
31 As *determinants* for BP control or treatment intensification we included socio-demographic variables  
32  
33 (age in year], gender, smoking history, alcohol use, marital status, and educational status), hospital  
34  
35 type (general/specialized), cardiometabolic comorbid illnesses (diabetes mellitus [DM], dyslipidemia,  
36  
37 kidney disease, heart failure/myocardial infarction), uncontrolled BP ( $\geq 140/90$  mm Hg) at the prior  
38  
39 visit, duration of antihypertensive treatment in year, treatment adherence (MMAS  $\geq 7$ : yes/no),  
40  
41 revisit schedule in month], and antihypertensive medications prescribed at prior visit.  
42  
43  
44

45  
46 Antihypertensive medication adherence was measured with the eight-point Morisky Medication  
47  
48 adherence scale (MMAS-8), which has been previously validated for hypertensive patients.[17,18]  
49  
50 The scale was translated into two Ethiopian languages (Amharic and Tigrigna) according to the  
51  
52 method described by Beaton *et al.*[19] A sum score of seven or more (maximum eight) was  
53  
54 considered to be adherent to antihypertensive medication; i.e. MMAS  $\geq 7$ . [17] For a sensitivity  
55  
56 analyses, we used a lower level of adherence with a cut-off of MMAS  $\geq 6$ . The revisit schedule period  
57  
58  
59  
60

1  
2  
3 in months was calculated by taking the difference in days between the index and prior visits divided  
4  
5 by 30.  
6

### 7 **Sample size**

8  
9 Achieved sample size was based on an estimated 30% prevalence of controlled BP among treated  
10  
11 hypertensive patients in Ethiopia [8,15] and a single proportion sample size calculation formula. The  
12  
13 total sample size was 984 (164 per hospital) with 0.80 power, 95% confidence interval, 3% margin of  
14  
15 error, and an estimated 10% none response rate, or incomplete/irretrievable patient records.  
16  
17

### 18 **Statistical analyses**

19  
20 Descriptive statistics were used to summarize socio-demographic, disease characteristics of the study  
21  
22 population, and nature and frequency of antihypertensive medications used. Multivariable logistic  
23  
24 regression analyses were applied to investigate determinants for achieving target BP at index visit,  
25  
26 and determinants for treatment intensification. Statistical significance was considered at p value <  
27  
28 0.05. Potential determinants with p < 0.2 in bivariable analyses were included into the multivariable  
29  
30 logistic model. Microsoft access 10 and SPSS version 22.0 statistical software was used for data entry  
31  
32 and analyses respectively.  
33  
34  
35  
36

### 37 **Sensitivity analyses**

38  
39 We performed sensitivity analyses using tighter BP targets at index visit (BP <130/80 mm Hg) for  
40  
41 those patients with diabetes mellitus (DM) and/or renal disease, and for all others participants the  
42  
43 standard BP target (BP <140/90 mm Hg). In addition, we performed a sensitivity analysis using a  
44  
45 different cut off for adherence.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

We were able to approach 968 patients at six public hospitals in Ethiopia. Seventy-one patients were excluded from our analyses; eight refused to participate, six were not hypertensive, and 57 patients had no retrievable records or incomplete records (missing BP at index visit), resulting in a study population of 897 patients (Figure 1). The mean (SD) patient age was 57 (14) years, the majority (63%) of patients were female, most patients (65%) were married and 64% had no formal education or only attended primary school. Almost all (94%) had never smoked, nearly half (43%) consumed alcohol regularly or occasionally (Table 1). At index visit, 35% study participants had at least one recorded comorbid illness, predominantly DM (Table 1).

**Table 1 Characteristics of ambulatory hypertensive patients at two visits, Ethiopia**

Characteristics	Index visit	Prior visit
<b>Demographics</b>		
Age (mean, SD), Year	57 (14)	
Female (n, %)	551 (63)	
Smoking (n, %)	57 (6)	
Alcohol use (n, %)	378 (43)	
Married (n, %)	567 (65)	
Education (n, %)		
University/college education	170 (20)	
Secondary education	141 (16)	
Primary or no formal education	557 (64)	
<b>Setting</b>		
Specialized hospitals: both from Addis Ababa (n, %)		
Tikur Anbessa Hospital	139 (16)	
St. Paul's Hospital	153 (17)	
General hospitals: all from Tigray, except Yekatit 12 from Addis Ababa (n, %)		
St. Mary Axum Hospital	139 (16)	
Mekelle Hospital	152 (17)	
Lemlem Karl Maychew Hospital	155 (17)	
Yekatit 12 Hospital	159 (18)	
<b>Disease characteristics</b>		
Blood pressure (BP)		
Systolic BP (Mean, SD)	139 (21)	144 (22)
Diastolic BP (Mean, SD)	84 (11)	85 (13)
Controlled BP (<140/90 mm Hg) (n, %)	335 (37)	231 (27)
Controlled BP (<130/80 mm Hg for DM &/or kidney diseases, otherwise <140/90 mm Hg) (n, %)	268 (30)	202 (24)
Cardiometabolic comorbid illnesses (n, %)		
Diabetes Mellitus	227 (25)	198 (22)
Dyslipidemia	57 (6)	45 (5)
Renal diseases	25 (3)	23 (3)
Heart failure / myocardial infarction	72 (8)	60 (7)
<b>Antihypertensive treatment characteristics</b>		
Drug class (n, %)		
ACE inhibitors	503 (56)	494 (55)
Enalapril	499 (56)	492 (55)
Lisinopril or captopril	4 (0.4)	2 (0.2)
Beta blockers	167 (19)	166 (19)
Atenolol	148 (17)	147 (16)
Propranolol	9 (1)	8 (1)
Metoprolol or carvedilol	10 (1)	11 (1)
Calcium channel blockers	449 (50)	439 (49)
Nifedipine	381 (43)	389 (43)
Amlodipine or felodipine	68 (8)	50 (6)
Diuretics #	498 (56)	486 (54)
Hydrochlorothiazide	428 (48)	421 (47)
Furosemide	76 (9)	71 (8)
Spironolactone	72 (8)	66 (7)
Others (methyldopa, nitrates or losartan)	19 (2)	13 (1)
Duration of therapy years (mean, SD)	6.6 (7)	
Revisit schedule in months (mean, SD)	2.3 (2.0)	
Adherence (MMAS $\geq$ 7) (n, %)	355 (40)	
Therapy (n, %)		
Monotherapy	343 (38)	363 (41)
Multidrug therapy	550 (62)	521 (59)
Treatment intensified in patients with uncontrolled BP at index visit (n=540) * (n, %)	123 (23)	

Mono/Multidrug therapy is limited to antihypertensive medications. \*For 22 of 562 patients with uncontrolled BP at the index visit the medication history was not complete. Treatment intensification could thus only be calculated for 540 patients. #Some patients had more than one type of diuretics.

1  
2  
3 Thirty-seven percent (n=335) of the participants had controlled BP at the index visit (Table 1). In our  
4  
5 sensitivity analyses, applying the stricter BP target for patients with DM and/or renal disease  
6  
7 (BP<130/80 mm Hg), the proportion of patients with controlled BP dropped to 27% (n=231).  
8  
9

10 Only, 23% of 540 patients with uncontrolled BP and complete medication history had their  
11  
12 treatment intensified (Table 1). For 22 (4%) of 562 patients with uncontrolled BP at the index visit,  
13  
14 the medication history was not complete, either the dose and/or administration frequency were  
15  
16 missing. The antihypertensive medication adherence rate (MMAS  $\geq$  7) was 40%, (Table 1), and 57%  
17  
18 for the lower MMAS  $\geq$  6 cut off (Supplement Table 1).  
19  
20

21 Overall, angiotensin-converting-enzyme (ACE) inhibitors were the most commonly prescribed  
22  
23 group of drugs (n = 503) followed by diuretics (n = 498) (Table 1). Medication use was quite similar  
24  
25 on both visits. At the index visit 62% of included patients were prescribed a multidrug treatment  
26  
27 regimens and 45% patients took two antihypertensive agents (Supplement Table 2). Most (38 %) of  
28  
29 the 343 patients on monotherapy had diuretics prescription (n=127).  
30  
31  
32

### 33 **Determinants of BP Control**

#### 34 *BP <140/90 mm Hg (primary analysis)*

35  
36 According to our multivariable logistic regression model (Table 2), factors significantly associated  
37  
38 with achieving target BP at the index visit were age (OR 0.99 [95% CI: 0.98; 1.00]), follow-up at  
39  
40 general hospitals (OR 1.89 [95% CI: 1.26; 2.83]), inadequately controlled BP at prior visit (OR 95% CI:  
41  
42 0.30 [0.21; 0.43]), longer treatment duration per year (OR 1.04 [95% CI: 1.01; 1.06]), and prescribed  
43  
44 diuretics (OR 0.68 [95% CI: 0.50; 0.94]).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2 Determinants of achieving target BP (BP < 140/90) at index visit in ambulatory hypertension patients**

Variables	Controlled BP		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), year	58 (13)	56 (15)	#0.99 [0.98; 1.00]	*0.99 [0.98; 1.00]	
Gender (n, %)	Male	219 (67)	109 (33)	Ref	
	Female	331 (60)	220 (40)	*1.34 [1.00; 1.78]	1.12 [0.80; 1.55]
Smoking (n, %)	No	514 (62)	312 (38)	Ref	
	Yes	37 (65)	20 (35)	0.89 [0.51; 1.56]	
Alcohol use (n, %)	No	310 (63)	184 (37)	Ref	
	Yes	232 (61)	146 (39)	1.06 [0.81; 1.40]	
Marital status (n, %)	Single	187 (60)	124 (40)	Ref	
	Married	359 (63)	208 (37)	0.87 [0.66; 1.16]	
Educational status (n, %)	College/University	110 (65)	60 (35)	Ref	
	Secondary	86 (61)	55 (39)	1.17 [0.74; 1.86]	
	Primary /not formal	345 (62)	212 (38)	1.13 [0.79; 1.61]	
Hospital type (n, %)	Specialized	199 (68)	93 (32)	Ref	
	General	363 (60)	242 (40)	*1.43 [1.06; 1.92]	*1.89 [1.26; 2.83]
<b>Disease characteristics (n, %)</b>					
Diabetes Mellitus	No	413 (62)	257 (38)	Ref	
	Yes	149 (66)	78 (34)	0.84 [0.61; 1.15]	
Dyslipidemia	No	523 (62)	317 (38)	Ref	
	Yes	39 (68)	18 (32)	0.76 [0.43; 1.35]	
Renal disease	No	542 (62)	330 (38)	Reference	
	Yes	20 (80)	5 (20)	#0.41 [0.15; 1.10]	0.58 [0.19; 1.71]
Heart failure/ MI at	No	518 (63)	307 (37)	Ref	
	Yes	44 (61)	28 (39)	1.07 [0.66; 1.76]	
Controlled BP at prior visit	No	424 (68)	199 (32)	*0.37 [0.27; 0.51]	*0.30 [0.21; 0.43]
	Yes	102 (44)	129 (56)	Ref	
<b>Antihypertensive Treatment characteristics</b>					
Duration of therapy, years (mean, SD)	6.2 (6.4)	7.4 (8.3)	#1.02 [1.00; 1.04]	*1.04 [1.01; 1.06]	
Adherent (MMAS $\geq 7$ ) (n, %)	No	319 (60)	212 (40)	Ref	
	Yes	233 (66)	122 (34)	#0.79 [0.60; 1.04]	0.80 [0.58; 1.09]
Revisit schedule in months (Mean, SD)	2.2 (1.4)	2.0 (1.2)	*0.89 [0.82; 0.97]	0.91 [0.82; 1.02]	
Therapy at prior visit (n, %)	Monotherapy	225 (62)	138 (38)	Ref	
	Multidrug	326 (63)	195 (37)	0.98 [0.74; 1.29]	
<b>Antihypertensive medications at prior visit</b>					
ACE inhibitors (n, %)	No	259 (64)	144 (36)	Ref	
	Yes	303 (61)	191 (39)	1.13 [0.86; 1.49]	
Beta blockers (n, %)	No	472 (65)	259 (35)	Ref	
	Yes	90 (54)	76 (46)	*1.54 [1.09; 2.16]	1.42 [0.95; 2.10]
Calcium channel blockers (n, %)	No	290 (63)	168 (37)	Ref	
	Yes	272 (62)	167 (38)	1.06 [0.81; 1.39]	
Diuretics (n, %)	No	243 (59)	168 (41)	Reference	
	Yes	319 (66)	167 (34)	*0.76 [0.58; 0.99]	*0.68 [0.50; 0.94]

Only patients with available data were included in the analyses, therefore numbers may sometimes differ from Table 1. Percentages are calculated per a row. Statistically significant values: \* $p < 0.05$  at 95% CI. Variables with # $p < 0.20$  or \* $p < 0.05$  in the bivariable model were included in the multivariable model. Mono/Multidrug therapy was for antihypertensive medications.

1  
2  
3 Sensitivity (secondary) analysis  
4

5 *BP <130/80 mm Hg for patients with DM and/or renal disease, for all other patients <140/90 mm Hg.*  
6

7  
8 In this secondary analyses uncontrolled BP at the prior visit had a negative effect on achieving target  
9  
10 BP at the index visit (OR 0.25 [95% CI: 0.17; 0.37]). Medications prescribed during the prior visit,  
11  
12 except diuretics (OR 0.60 [95% CI: 0.40; 0.90]), were not significantly associated with achieving  
13  
14 controlled BP at the index visit. Unlike the primary analyses, age, treatment duration, and hospital  
15  
16 type did not show statistically significant effects on index visit BP status (Supplement Table 3).  
17

### 18 19 **Determinant of treatment intensification**

20  
21 The only statistically significant determinant for treatment intensification in the multivariable  
22  
23 analyses was longer treatment duration (OR 1.05 [95% CI: 1.02; 1.09]), Table 3.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3 Treatment intensification determinants for ambulatory hypertension patients with uncontrolled BP at index visit**

Variables	Treatment intensified		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), Year	57 (13)	60 (13)	#1.02 [1.00; 1.03]	1.02 [1.00; 1.04]	
Gender (n, %)	Male	167 (80)	41 (20)	Ref	
	Female	241 (75)	80 (25)	#1.35 [0.88; 2.07]	1.47 [0.91; 2.37]
Smoking (n, %)	No	383 (77)	113 (23)	Ref	
	Yes	27 (79)	7 (21)	0.88 [0.37; 2.07]	
Alcohol use (n, %)	No	225 (76)	73 (25)	Ref	
	Yes	180 (80)	44 (20)	0.75 [0.49; 1.15]	
Marital status (n, %)	Single	138 (77)	42 (23)	Ref	
	Married	269 (78)	76 (22)	0.93 [0.60; 1.43]	
Educational status (n, %)	College/University	82 (78)	23 (22)	Ref	
	Secondary	58 (70)	25 (30)	1.54 [0.80; 2.97]	
	Primary/not formal education	262 (79)	70 (21)	0.95 [0.56; 1.62]	
Hospital type (n, %)	Specialized	137 (73)	51 (27)	Ref	
	General	280 (80)	72 (21)	#0.69 [0.46; 1.04]	0.83 [0.51; 1.37]
<b>Disease characteristics (n, %)</b>					
Diabetes Mellitus at index visit	No	311 (79)	84 (21)	Ref	
	Yes	106 (73)	39 (27)	#1.36 [0.88; 2.11]	1.10 [0.67; 1.81]
Dyslipidemia at index visit	No	388 (77)	113 (23)	Reference	
	Yes	29 (74)	10 (26)	1.19 [0.56; 2.50]	
Renal disease at index visit	No	403 (77)	118 (23)	Ref	
	Yes	14 (74)	5 (26)	1.22 [0.43; 3.45]	
Heart Failure / MI at index visit	No	384 (77)	112 (23)	Ref	
	Yes	33 (75)	11 (25)	1.14 [0.56; 2.33]	
Controlled BP at prior visit	No	312 (77)	96 (24)	#1.50 [0.85; 2.66]	1.38 [0.76; 2.50]
	Yes	83 (83)	17 (17)	Ref	
<b>Antihypertensive treatment characteristics</b>					
Duration of therapy yrs (mean SD)	5.7 (6.1)	8.1 (7.4)	*1.05 [1.02; 1.08]	*1.05 [1.02; 1.09]	
Adherence (MMAS $\geq$ 7) (n, %)	No	232 (76)	73 (24)	Ref	
	Yes	178 (78)	49 (22)	0.88 [0.58; 1.32]	
Therapy at prior visit (n, %)	Monotherapy	168 (76)	53 (24)	Ref	
	Multidrug therapy	249 (78)	70 (22)	0.89 [0.59; 1.34]	

Statistically significant values: \*p < 0.05 at 95% CI. Variable with #p < 0.2 or \*p < 0.05 in the bivariable model were included in the multivariable model. Percentages are calculated per a row. Treatment intensification was calculated for 540 patients who had complete medication history (including dose and frequency) on both visits and uncontrolled BP at index visit.



## DISCUSSION

In this study, nearly two-thirds of patients on medication had uncontrolled BP. Drugs were prescribed from four antihypertensive drug classes, ACE-inhibitors, diuretics, CCBs, and BBs. Generally, a single specific agent (over 90%) was prescribed within a class, enalapril, hydrochlorothiazide, nifedipine, and atenolol respectively. Age of patients, uncontrolled BP at prior visit, and a treatment regimen containing diuretics contributed to poorer BP control. Whereas follow-up in a general hospital as compared to a specialized hospital, and longer treatment duration were associated with a better BP control. Duration of therapy on antihypertensive medication was the only, albeit modestly (also for BP control), significant contributing factor for treatment intensification.

Most other studies in Africa, 41 out of 44, showed a lower proportion of patients with controlled BP (these studies reported levels of control ranging from <1% to 33%) than our study.[8] The reported wide variation could be explained by population differences and variation in study set-up. In comparison with studies in western countries, the percentage of patients with adequately controlled BP, and those who received treatment intensification was lower in our study than in North American countries but similar to some European countries.[20,21] These differences may be explained in part by different recommendations between national guidelines. However, as reported elsewhere, it is not only differences between guidelines, but also how much effort countries put in implementation of these recommendations.[21] While the Ethiopian guideline is similar to the USA guidelines [20,22], possible differences in implementation, due to typical African factors including resource limitations, low priority for communicable diseases, and healthcare providers' behavior and skills may in part explain the low level of BP control.[23]

In our study one of the determinants for achieving target BP was the healthcare setting. Patients referred to the specialized hospitals may be more complex – in terms of comorbidities or severity of

1  
2  
3 hypertension. Hence, it may not be that surprising that patients in these hospitals are more likely to  
4  
5 have inadequately controlled BP. Younger age was another significant determinant for achieving  
6  
7 target BP. Prescribers in our study may have accepted higher BP in older patients, possibly because  
8  
9 of tolerability or perceived lack of need for tight BP control. Recent evidence, however, suggests that  
10  
11 “the lower is the better” also in older patients.[24,25] Nevertheless, guidelines lack consistency on  
12  
13 BP targets for elderly,[26] especially when patients are frail doctors may not aim for tight BP control.  
14  
15 Another determinant of BP control was the type of medication prescribed. Most of our study  
16  
17 participants received diuretics, the first line antihypertensive agents. We have no data in which order  
18  
19 medication was initiated; therefore, we can only speculate why treatment regimens containing these  
20  
21 drugs did not show better BP control. Since, three-quarters of diuretics-containing regimens in our  
22  
23 study existed of two drugs only (S 2 Tab), patients may need additional therapy. However, physicians  
24  
25 may have been reluctant to intensify treatment further, because of fear for risk of too drastic BP  
26  
27 lowering (e.g. resulting in dehydration when increasing diuretic doses).  
28  
29  
30  
31  
32

33  
34 Only one fifth of patients with uncontrolled BP at the index visit had their treatment intensified.  
35  
36 Longer treatment duration was the only statistically significant determinant for intensification.  
37  
38 Possibly, it took a while before prescribers would intensify treatment. Ultimately, the lack of BP  
39  
40 control at the prior visit was the strongest predictor of patients not having controlled BP at index  
41  
42 visit. This seems to suggest some level of ‘clinical inertia’, where doctors are slow to respond to  
43  
44 clinical parameters indicating a need to step up therapy. However, it may also be explained by true  
45  
46 therapy resistant hypertension (although only 17% of patients received three or more  
47  
48 antihypertensive agents at the prior visit) or possibly medication adherence.[27-30] Medication  
49  
50 adherence is known as an important determinant for controlling hypertension.[31] In our study using  
51  
52 a self-reported scale, less than half of the patients were adherent. Surprisingly, there was no  
53  
54 significant association with BP control (Table 2, Supplement Table 1).  
55  
56  
57  
58  
59  
60

1  
2  
3 An interesting finding was that more hypertensive women than men were included in our study, and  
4  
5 that so few patients smoked. The reason why more women were included could be that  
6  
7 hypertension is truly more prevalent in Ethiopian females as shown in a recent paper,[13] although a  
8  
9 meta-analysis showed almost equal prevalence.[15] Another explanation may be that women with  
10  
11 hypertension are seeking care more regularly than man. However, women were not more likely than  
12  
13 man to have controlled BP or their treatment intensified. Our study was largely performed in urban  
14  
15 areas, which have the highest prevalence of hypertension in Ethiopia that is attributed to adoption of  
16  
17 a Western life-style.[15] Still, our patient population looks very different from that in European or  
18  
19 USA studies; i.e. with few smokers and few patients with (known) cardiometabolic comorbidities.  
20  
21  
22

### 23 24 **Strength and limitations**

25  
26 As far as we are aware, this was the first study of its kind in Ethiopia covering a relatively diverse  
27  
28 population. Our data included patients from outpatient clinics of hospitals in the capital city and  
29  
30 northern region of Ethiopia.  
31  
32

33 A limitation of our study was the validity of the BP measure used. We analysed BP measurements  
34  
35 as recorded in patients' medical records which reflected actual clinical practice, but may be subject  
36  
37 to recording and measurement error. It is not clear how prescribers considered measurement  
38  
39 variability or if any attempt was made to avoid 'white-coat' hypertension, e.g. by repeating BP  
40  
41 measurement. Still, many observational studies use medical records – with data collected in routine  
42  
43 practice - as data source. Future studies may consider using standardized assessment of BP  
44  
45 evaluation. Another limitation is that medical records did not include extensive or well-structured  
46  
47 patient information. For example, comorbidities may be underreported. For this reason, we limited  
48  
49 evaluated comorbidities to cardiometabolic diseases as these are relevant to hypertension prognosis  
50  
51 and treatment and are more likely to have been recorded in the charts. This study focused on public  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 secondary and specialized hospitals, therefore the result may not be generalizable to other settings  
4  
5 such as private practices and primary health care centers.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**CONCLUSION**

Nearly two-thirds of patients on antihypertensive medication did not achieve target BP during routine clinical practice, and only a quarter of them received treatment intensification. Our data suggest that intervention programs to improve BP control may first target patients with repeated lack of BP control and intensify treatment more promptly. Especially, in elderly patients and those treated in specialized hospitals.

For peer review only

## Acknowledgments

Authors wish to thank study participants, data collectors, and study hospital administrators who contributed to this study.

## Contribution

D.F. Berhe, K. Taxis and P. Mol designed and performed the research, analyzed, and interpreted the data. Flora M Haaijer-Ruskamp, Afework Mulugeta, and Yewondwossen Tadesse Mengistu designed the study. All authors participated in writing the manuscript, also read and approved the final version.

**Conflict of Interest:** There are no competing interests to declare.

## Funding

The study was part of a PhD project to the first author funded by Netherlands Organization for International Cooperation in Higher Education (NUFFIC).

## Ethics approval

This study was approved by Ethiopian Health Research Ethical Review Committees of (i) the College of Health Sciences, Mekelle University, (ii) St Paul's Hospital Millennium Medical College, and (iii) the Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University. All individual participants included in this study consented to participation.

## Data sharing statement

No additional data are available for this specific study.

## REFERENCES

- (1) World Health Organization. A global brief on hypertension: Silent killer, global public health crisis. 2013. Available from [http://apps.who.int/iris/bitstream/10665/79059/1/WHO\\_DCO\\_WHD\\_2013.2\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf) [accessed on 2016-05-17]
- (2) Fuchs FD. Why do black Americans have higher prevalence of hypertension? an enigma still unsolved. *Hypertension* 2011;57:379-80.
- (3) Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and  $\beta$ -adrenergic blockers? A systematic review. *BMC med* 2013;11:1.
- (4) Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. *Circulation* 2005;112:3562-3568.
- (5) Sagnella G. Why is plasma renin activity lower in populations of African origin? *J Hum Hypertens* 2001;15:17-25.
- (6) Dennison CR, Peer N, Steyn K, *et al.* Determinants of hypertension care and control among peri-urban Black South Africans: The HiHi study. *Ethn Dis* 2007;17:484-91.
- (7) James PA, Oparil S, Carter BL, *et al.* 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014;311:507-20.
- (8) Kayima J, Wanyenze RK, Katamba A, *et al.* Hypertension awareness, treatment and control in Africa: a systematic review. *BMC Cardiovasc Disord* 2013;13:54.
- (9) Kessler CS, Joudeh Y. Evaluation and treatment of severe asymptomatic hypertension. *Am Fam Physician* 2010;81:470-6.
- (10) van de Vijver S, Akinyi H, Oti S, *et al.* Status report on hypertension in Africa-consultative review for the 6th Session of the African Union Conference of Ministers of Health on NCD's. *Pan Afr Med J* 2013;16:38.
- (11) Naicker S, Plange-Rhule J, Tutt RC, *et al.* Shortage of healthcare workers in developing countries-Africa. *Ethn Dis* 2009;19 Suppl 1:S160-4.
- (12) Mancia G, Fagard R, Narkiewicz K, *et al.* 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Blood Press* 2013;22:193-278.
- (13) Abebe SM, Berhane Y, Worku A, *et al.* Prevalence and associated factors of hypertension: a cross sectional community based study in Northwest Ethiopia. *PLoS One* 2015;10:e0125210.

- 1  
2  
3 (14) Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa:  
4 a systematic analysis. *PLoS One* 2014;9:e104300.  
5  
6 (15) Kibret KT, Mesfin YM. Prevalence of hypertension in Ethiopia: a systematic meta-analysis. *Public*  
7 *Health Reviews* 2015;36:14.  
8  
9 (16) Shukrala F, Gabriel T. Assessment of prescribing, dispensing, and patient use pattern of  
10 antihypertensive drugs for patients attending outpatient department of Hiwot Fana Specialized  
11 University Hospital, Harar, Eastern Ethiopia. *Drug Des Devel Ther* 2015; 9:519-23.  
12  
13 (17) Lee GK, Wang HH, Liu KQ, *et al.* Determinants of medication adherence to antihypertensive  
14 medications among a Chinese population using Morisky Medication Adherence Scale. *PLoS One*  
15 2013;8:e62775.  
16  
17 (18) Morisky DE, Ang A, Krousel-Wood M, *et al.* Predictive validity of a medication adherence  
18 measure in an outpatient setting. *J Clin Hypertens* 2008;10:348-54.  
19  
20 (19) Beaton DE, Bombardier C, Guillemin F, *et al.* Guidelines for the process of cross-cultural  
21 adaptation of self-report measures. *Spine* 2000;25:3186-91.  
22  
23 (20) Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment  
24 intensification, and control in Western Europe and the United States. *Arch Intern Med* 2007;167:141-  
25 7.  
26  
27 (21) Wolf-Maier K, Cooper RS, Kramer H, *et al.* Hypertension treatment and control in five European  
28 countries, Canada, and the United States. *Hypertension* 2004;43:10-7.  
29  
30 (22) FMHACA. Hypertension: Standard Treatment Guidelines for General Hospitals, Ethiopia. Third  
31 Edition ed.: Food, Medicine and Health Care Administration and Control Authority(FMHACA); 2014.  
32 p. 47-53.  
33  
34 (23) Nulu S, Aronow WS, Frishman WH. Hypertension in Sub-Saharan Africa: A Contextual View of  
35 Patterns of Disease, Best Management, and Systems Issues. *Cardiol Rev* 2016;24:30-40.  
36  
37 (24) SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control.  
38 *N Engl J Med* 2015;373:2103-16.  
39  
40 (25) Perkovic V, Rodgers A. Redefining blood-pressure targets - SPRINT starts the marathon. *N Engl J*  
41 *Med* 2015;373:2175-78.  
42  
43 (26) Alhawassi TM, Krass I, Pont LG. Hypertension in older persons: A systematic review of national  
44 and international treatment guidelines. *J Clin Hypertens* 2015;17:486-92.  
45  
46 (27) Phillips LS, Branch WT, Cook CB, *et al.* Clinical inertia. *Ann Intern Med* 2001;135:825-34.  
47  
48 (28) Moser M. Physician or clinical inertia: what is it? Is it really a problem? And what can be done  
49 about it? *J Clin Hypertens* 2009;11:1-4.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 (29) Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of  
4 resistant hypertension in treated hypertensive populations. *Am J Hypertens* 2015;28:355-61.  
5

6 (30) Nansseu JR, Noubiap JJ, Mengnjo MK, *et al.* The highly neglected burden of resistant  
7 hypertension in Africa: a systematic review and meta-analysis. *BMJ Open* 2016;6:e011452.  
8

9  
10 (31) Corrao G, Parodi A, Nicotra F, *et al.* Better compliance to antihypertensive medications reduces  
11 cardiovascular risk. *J Hypertens* 2011;29:610-8.  
12  
13

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A RETROSPECTIVE COHORT STUDY IN EHTIOPIA




Figure 1 Flow chart for case inclusion for analysis

## HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A RETROSPECTIVE COHORT STUDY IN EHTIOPIA

**Supplement Table 1 Determinants of achieving target BP (BP < 140/90) at index visit ambulatory hypertension patients (sensitivity analysis with adherence definition of MMAS ≥ 6)**

Variables	Controlled BP		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), year	58 (13)	56 (15)	#0.99 [0.98; 1.00]	*0.99 [0.98; 1.00]	
Gender (n, %)	Male	219 (67)	109 (33)	Ref	
	Female	331 (60)	220 (40)	*1.34 [1.00; 1.78]	1.12 [0.81; 1.55]
Hospital type (n, %)	Specialized	199 (68)	93 (32)	Ref	
	General	363 (60)	242 (40)	*1.43 [1.06; 1.92]	*1.88 [1.25; 2.81]
<b>Disease characteristics at index visit (n, %)</b>					
Renal disease	No	542 (62)	330 (38)	Reference	
	Yes	20 (80)	5 (20)	#0.41 [0.15; 1.10]	0.60 [0.20; 1.79]
Controlled BP at <b>prior visit</b>	No	424 (68)	199 (32)	*0.37 [0.27; 0.51]	*0.30 [0.21; 0.43]
	Yes	102 (44)	129 (56)	Ref	
<b>Antihypertensive Treatment characteristics</b>					
Duration of therapy, years (mean, SD)	6.2(6.4)	7.4 (8.3)	#1.02 [1.00; 1.04]	*1.04 [1.02; 1.06]	
Adherent (MMAS ≥ 6) (n, %)	No	237 (63)	140 (37)	Ref	
	Yes	315 (62)	194 (38)	1.04 [0.79; 1.37]	1.14 [0.83; 1.56]
Revisit schedule in months (Mean, SD)	2.2 (1.4)	2.0 (1.2)	*0.89 [0.82 ;0.97]	0.91 [0.82; 1.02]	
Beta blockers (n, %)	No	472 (65)	259 (35)	Ref	
	Yes	90 (54)	76 (46)	*1.54 [1.09; 2.16]	1.45 [0.98; 2.15]
Diuretics (n, %)	No	243 (59)	168 (41)	Reference	
	Yes	319 (66)	167 (34)	*0.76 [0.58; 0.99]	*0.68 [0.50; 0.94]

Variables with #p < 0.20 or \*p < 0.05 in the bivariable model were included in this multivariable model (sensitivity analysis).

**Supplement Table 2 Prescribed antihypertensive medication(s) per patient**

Drug prescribed per case	At Index visit (n <sup>*</sup> =887), %	At Prior visit (n <sup>*</sup> =882), %
D (Diuretics)	14.3	15.0
C (CCBs)	13.0	13.7
A (ACE inhibitors)	9.9	11.0
B (BBs)	0.8	1.4
DC	9.4	8.6
DA	17.0	16.6
CA	11.5	10.2
AB	2.6	2.4
CB	2.4	2.7
DB	2.0	1.5
DCB	1.5	1.1
DCA	6.1	6.1
ACB	3.7	3.5
DAB	2.7	2.5
DABC	3.2	3.7

CCBs, calcium channel blockers; ACE, Angiotensinogen Converting Enzyme; BBs; Beta Blockers

\*The table did not include rarely used medication categories. These drugs were methyldopa, losartan, hydralazine, and nitrates and in combination with others or as a monotherapy.

**Supplement Table 3 Sensitivity analyses: determinants for controlled hypertension at alternative BP target (BP <130/80 mm Hg) for patients with DM and/or renal disease, and all other patients BP <140/90 mm Hg)**

Variables	Controlled BP		Bivariable OR [95% CI]	Multivariable OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD)	58 (13)	56 (15)	#0.99 [0.98; 1.00]	0.99 [0.98; 1.00]	
Gender (n, %)	Male	244 (74)	84 (26)	Ref	
	Female	373 (68)	178 (32)	*1.39 [1.02; 1.88]	1.30 [0.87; 1.95]
Smoking (n, %)	No	572 (69)	254 (31)	Ref	
	Yes	45 (79)	12 (21)	#0.60 [0.31; 1.16]	1.05 [0.50; 2.24]
Alcohol use (n, %)	No	354 (72)	140 (28)	Ref	
	Yes	254 (67)	124 (33)	#1.23 [0.92; 1.65]	1.54 [1.07; 2.21]
Marital status (n, %)	Single	207 (67)	104 (33)	Ref	
	Married	406 (72)	161 (28)	#0.79 [0.59; 1.06]	0.82 [0.56; 1.18]
Educational status (n, %)	College/University	123 (72)	47 (28)	Ref	
	Secondary	103 (73)	38 (27)	1.21 [0.83; 1.77]	
	Primary /not formal	381 (68)	176 (32)	0.97 [0.59; 1.59]	
Hospital type (n, %)	Specialized	217 (74)	75 (26)	Ref	
	General	412 (68)	193 (32)	1.36 [0.99; 1.85]	1.17 [0.75; 1.82]
<b>Disease characteristics (n, %)</b>					
Dyslipidemia at index visit	No	583 (69)	257(31)	Ref	
	Yes	46 (81)	11 (19)	#0.54 [0.28; 1.06]	0.47 [0.20; 1.10]
Heart Failure / MI at index visit	No	578 (70)	247 (30)	Ref	
	Yes	51 (71)	21 (29)	0.96 [0.57; 1.64]	
Controlled BP at prior visit	No	501 (77)	151 (23)	*0.25 [0.18; 0.35]	*0.25 [0.17; 0.37]
	Yes	92 (46)	110 (55)	Ref	
<b>Antihypertensive treatment characteristics</b>					
Duration of therapy years (mean, SD)	7.0 (7.3)	5.8 (6.9)	#0.98 [0.96; 1.00]	0.99 [0.97; 1.02]	
Adherence (MMAS-8 ≥ 7) (n, %)	No	373 (70)	158 (29)	Ref	
	Yes	246 (69)	109 (31)	1.04 [0.78; 1.40]	
Revisit schedule in months (Mean, SD)	2.4 (2.1)	2.0 (1.2)	*0.88 [0.81; 0.97]	0.94 [0.84; 1.06]	
Therapy at prior visit (n, %)	Monotherapy	240 (66)	123 (34)	Ref	
	Multidrug therapy	378 (73)	143 (27)	*0.74 [0.55; 0.99]	1.02 [0.69; 1.51]
<b>Antihypertensive medications at prior visit</b>					
ACE inhibitors (n, %)	No	274 (68)	129 (32)	Ref	
	Yes	355 (72)	139 (28)	0.83 [0.62; 1.11]	
Beta blockers (n, %)	No	511 (70)	220 (30)	Ref	
	Yes	118 (71)	48 (29)	0.95 [0.65; 1.37]	
Calcium channel blockers (n, %)	No	312 (68)	146 (32)	Ref	
	Yes	317 (72)	122 (28)	#0.82 [0.62; 1.10]	0.88 [0.59; 1.31]
Diuretics (n, %)	No	276 (67)	135 (33)	Ref	
	Yes	353 (73)	133 (27)	#0.77 [0.58; 1.03]	*0.60 [0.40; 0.90]

1  
2  
3 Only patients with available data are included in the analyses, therefore numbers may sometimes differ from Table 1.  
4 Percentages are calculated per a row. Statistically significant values: \* $p < 0.05$  at 95% CI. Variables with # $p < 0.20$  or \* $p < 0.05$  in  
5 the bivariable model were included in the multivariable model. DM: diabetes mellitus  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	12
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9, also on Figure 1 (Page 24)
		(b) Give reasons for non-participation at each stage	9, also on Figure 1 (Page 24)
		(c) Consider use of a flow diagram	Figure 1 (Page 24)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	10
		(c) Summarise follow-up time (eg, average and total amount)	10 (Revisit schedule)
Outcome data	15*	Report numbers of outcome events or summary measures over time	11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12, 14
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplement Tables (Page 25/27)
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	15
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A RETROSPECTIVE COHORT STUDY IN ETHIOPIA

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015743.R1
Article Type:	Research
Date Submitted by the Author:	31-Mar-2017
Complete List of Authors:	Berhe, Derbew Fikadu; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology; Mekelle University, Department of Pharmacy Taxis, Katja; University of Groningen, Department of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics Haaijer-Ruskamp, Flora; University of Groningen, University Medical Center, Department of Clinical Pharmacy and Pharmacology Mulugeta, Afework; Mekelle University, School of Public Health Mengistu, Yewondwossen Tadesse; Addis Ababa University, College of Health Sciences, School of Medicine, Department of Internal Medicine Mol, Peter; University Medical Center Groningen, University Medical Center, Department of Clinical Pharmacy and Pharmacology
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics, Public health
Keywords:	Hypertension < CARDIOLOGY, Adult cardiology < CARDIOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

1  
2  
3 **HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A**  
4  
5 **RETROSPECTIVE COHORT STUDY IN EHTIOPIA**  
6

7 **Short title: hypertension treatment practices and determinants**  
8  
9

10  
11  
12 Derbew Fikadu Berhe<sup>1,2</sup>, Katja Taxis<sup>3</sup>, Flora M Haaijer-Ruskamp<sup>1</sup>, Afework Mulugeta<sup>4</sup>, Yewondwossen

13  
14 Tadesse Mengistu<sup>5</sup>, Peter GM Mol<sup>1</sup>  
15

16  
17 <sup>1</sup>Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical  
18  
19 Center Groningen, The Netherlands  
20

21 <sup>2</sup>Department of Pharmacy, College of Health Sciences, Mekelle University, Ethiopia  
22

23  
24 <sup>3</sup>Department of Pharmacy, Unit Pharmacotherapy, -epidemiology & economics, University of  
25  
26 Groningen, The Netherlands  
27

28 <sup>4</sup>School of Public Health, College of Health Sciences, Mekelle University, Ethiopia  
29

30  
31 <sup>5</sup>Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa  
32  
33 University, Ethiopia  
34

35  
36  
37  
38 Corresponding author:

39 Peter GM Mol

40  
41 University Medical Center Groningen, UMCG

42  
43 Department of Clinical Pharmacy and Pharmacology, EB70

44  
45 Hanzeplein 1, PO BOX 30001, 9700 RB Groningen

46  
47 The Netherlands

48  
49 + 31 (0)50 363 8313, Fax. +31 (0)50 363 2812

50  
51 Email : p.g.m.mol@umcg.nl  
52

53  
54 Word count: 3,759

55  
56 Number of tables: 3, supplement tables: 5, and, Figure: 1

57  
58 References: 36  
59  
60

**ABSTRACT**

**Objectives:** We examined determinants of achieving blood pressure control in hypertensive patients and of treatment intensification in patients with uncontrolled blood pressure (BP).

**Design:** A retrospective cohort study in six public hospitals, Ethiopia

**Participants:** Adult ambulatory hypertensive patients with at least one previously prescribed antihypertensive medication in the study hospital.

**Outcome:** Controlled BP (<140/90 mm Hg), and treatment intensification of patients with uncontrolled BP.

**Results:** The study population comprised of 897 patients. Their mean age was 57 (SD 14) years, 63% were females, and 35% had one or more cardiometabolic comorbidities mainly diabetes mellitus. BP was controlled in 37% patients. Treatment was intensified for 23% patients with uncontrolled BP. In multivariable (logistic regression) analysis, determinants positively associated with controlled BP were treatment at general hospitals (OR 1.89 [95% CI: 1.26; 2.83]) compared to specialized hospitals, and longer treatment duration (OR 1.04 [95% CI: 1.01; 1.06]). Negatively associated determinants were previously uncontrolled BP (OR 0.30 [95% CI: 0.21; 0.43]), treatment regimens with diuretics (OR 0.68 [95% CI, 0.50; 0.94]), and age (OR 0.99 [95% CI: 0.98; 1.00]). The only significant – positive - determinant for treatment intensification was duration of therapy (OR 1.05 [95% CI: 1.02; 1.09]).

**Conclusions:** The level of controlled BP and treatment intensification practice in this study was low. The findings suggest the need for in-depth understanding and interventions of the identified determinants such as uncontrolled BP on consecutive visits, older age, and type of hospital.

**Key words:** hypertension, antihypertensive medication, blood pressure control, treatment intensification, ambulatory patients, Ethiopia, hospital, observational study

**STRENGTH AND LIMITATIONS**

- This is the first study that gives insight into determinants of hypertension treatment practice (level of BP control and treatment intensification) in a diverse population treated in public hospitals in Ethiopia.
- We analysed BP measurements as recorded in patient medical records, which reflect actual clinical practice, but may be subject to recording and measurement error.
- The finding of this study may not be generalizable to other settings such as private practice or primary health care centers in Ethiopia.

## BACKGROUND

Hypertension is a major risk factor for cardiovascular diseases and it is the leading cause of death and disability globally.[1] The World Health Organization (WHO) recently reported that 80% of deaths due to cardiovascular disease occur in low- and middle-income countries, with the highest death rate reported in African countries. The report also indicated that prevalence of hypertension in adults was higher in Africa (46%) than for instance in the US (35%).[1] Hypertension is also more prevalent among people from Africa living in Western world than among whites.[2] The population of African ancestry is characterized by high vascular contractility, extreme salt sensitivity, and low renin release.[3-5] Hence, over-activation of the sympathetic nervous system and renin-angiotensin-aldosterone system is more prevalent in this population, making them more vulnerable to high blood pressure. In addition, changes in environmental factors such as economic development, urbanization, and lifestyle have resulted in an epidemiological transition from infectious to non-communicable disease such as hypertension in the African region.[6]

Large clinical outcome studies have repeatedly shown that treating hypertension using evidence based antihypertensive treatment and/or adjusting life style improves cardiovascular outcomes.[7] However, achieving target blood pressure (BP) level remains a challenge in clinical practice. The majority of studies in Africa have shown that less than a third of patients achieve treatment goals.[8] Generally, four main factors have been identified that influence achieving controlled BP. First, there are factors intrinsic to the nature of the disease; in most cases hypertension is initially asymptomatic and this delays early prevention, diagnosis and treatment.[9] Second, poor treatment response may be due to patient-related factors such as age, gender, race, awareness and compliance to medication.[4,10] Third, these are healthcare system-related factors such as lack of effective hypertension prevention and treatment programs, and access to medications. Fourth, prescriber behavior, competences, and large patient-to-prescriber ratio affect hypertension prevention and

1  
2  
3 treatment outcomes. The majority of these factors have been extensively studied in western society;  
4  
5 however, little is known of their impact on BP control in developing nations. Some of these factors  
6  
7 may be unique to, or more pronounced in the African setting including low societal awareness,  
8  
9 priority to fight infectious diseases, and human resource limitations in particular the number of  
10  
11 available healthcare professionals.[6,11]  
12  
13

14  
15 Prevention and treatment strategies have been shown to be effective in optimizing BP control in  
16  
17 the western world.[12] Such programs may be relevant for the African setting. In order to guide  
18  
19 targeted interventions studies, identifying factors contributing to poor BP control in the African  
20  
21 setting are urgently needed. Studies on hypertension conducted to date in Ethiopia, the second  
22  
23 largest populous country (approximately 100 million) in Africa, have focused on determining  
24  
25 prevalence of the disease.[13-15] Prevalence is relatively low (10 – 30%), [1,13-15], but further data  
26  
27 on hypertension treatment practices are lacking.[16,17] Therefore, we aimed to assess the  
28  
29 proportion of patients treated for hypertension who had controlled BP and identify determinants for  
30  
31 achieving BP control in an Ethiopian setting. Additionally, we aimed to study whether treatment was  
32  
33 intensified in those patients with uncontrolled BP and identify the determinants for treatment  
34  
35 intensification.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Study design and setting

This retrospective cohort study was conducted in outpatient clinics of six public hospitals in Addis Ababa (capital city) and Tigray regional state, Ethiopia. We included two specialized hospitals (Addis Ababa), and four general hospitals, three from Tigray and one from Addis Ababa. Specialized (tertiary) hospitals are at the top tier of Ethiopian public healthcare system and serve up to five million population. The general (secondary) hospitals are estimated to serve 1-1.5 million population. Furthermore, patients including those with hypertension are usually treated first at a primary healthcare center.[18]

### Study population

Participants were approached while waiting for their appointment in the waiting area of hypertension outpatient clinics, where known hypertensive patients come for regular follow-up visits. They were recruited consecutively after giving consent. Hypertensive patients aged 18 years or above were included, if they had at least one previous antihypertensive medication prescription in the same hospital, and gave informed consent. Patients were identified based on self-reported hypertension or based on the mark on their pocket-size appointment card as being hypertensive. We verified in each clinic log-book (if available), and from individual patient medical records if patients met the inclusion criteria as they had indicated during the interviews.

Routine practice in the study hospitals is that nurses measure patient's blood pressure and assign the patient to a physician. The physician will then perform a consultation, confirm the hypertension diagnosis, and if necessary perform further examinations including rechecking BP, and renew or amend prescribed medication. Patients then collect their medicine from pharmacy outlets at the same hospital or if not available from private or community pharmacies.

## Data collection

Included patients were interviewed in the waiting area before they were seen by the physician. Data collected via interview were socio demographics, medication adherence, and treatment duration of antihypertensive medication(s). The socio demographics variables were age, sex, educational and marital status, alcohol use and smoking habits. Clinical information retrieved from medical records were BP measurements, medication prescribed, and comorbid illnesses, and information was retrieved for the *current visit* and the previous (*prior*) *visit*. Data were collected by professional nurses or pharmacists who were trained in using a dedicated case-report form. Data were collected between February and August 2015.

## Variables

### Outcome measures

We defined two *outcome measures*. First, for *BP control* we used the 'standard' definition of controlled BP, i.e., systolic BP/diastolic BP below 140/90 mm Hg at the current visit.[12] Second, we defined *treatment intensification* as an increase in dose of an antihypertensive drug and/or addition of one or more antihypertensive drug(s). Treatment intensification was calculated for those patients who had a complete medication history (including dose and administration frequency) at both current and prior visits and whose BP was not controlled at the current visit. A switch in drug class was not considered as treatment intensification.

### Explanatory variables

For *determinants* of BP control or treatment intensification, we included socio-demographic variables (age in year, gender, smoking history, alcohol use, marital status, and educational status), hospital type (general versus specialized), cardiometabolic comorbid illnesses (diabetes mellitus-DM, dyslipidemia, kidney disease, heart failure/myocardial infarction), uncontrolled BP ( $\geq 140/90$  mm Hg) at the prior visit, duration of antihypertensive treatment in year, treatment adherence with eight-



1  
2  
3 point Morisky Medication adherence scale, MMAS-8 ( $\geq 7$ : yes/no), visit schedule in month, and  
4  
5 antihypertensive medications prescribed at prior visit. For alcohol use and smoking habit,  
6  
7 participants were asked if they were active smokers or consume alcohol until our survey date, i.e  
8  
9 smoking history (Yes: current smokers, and No: never smoke or ex-smoker), alcohol use (Yes:  
10  
11 regularly or sometimes, and No: never consume alcohol). The visit schedule was calculated by taking  
12  
13 the difference in days between the current and prior visits divided by 30, i.e its indicates length of  
14  
15 time (duration) between the two follow-up visit expressed in months.  
16  
17

18  
19 Antihypertensive medication adherence was measured with the eight-point Morisky Medication  
20  
21 adherence scale (MMAS-8), which has been previously validated for hypertensive patients.[19,20]  
22  
23 The items of the scale are grouped into three aspects. The first aspect is about forgetting to take  
24  
25 medication sometimes (Item 1), and more specifically in the past two weeks (item 2), or under  
26  
27 special circumstances during travel/leaving home (item 4), and finally asking if medication was taken  
28  
29 yesterday (item 5). The second aspect is about intentionally stopping or cutting back medication  
30  
31 because of feeling worse (item 3) or because of a feeling that BP is under control (Item 6). The last  
32  
33 aspect relates to convenience (item 7) or inconvenience frequency of difficult times to take  
34  
35 medication (item 8). The scale was translated into two Ethiopian languages (Amharic and Tigrigna)  
36  
37 according to the method described by Beaton *et al.*[21] A total score of seven or more (maximum  
38  
39 eight) was considered to be adherent to antihypertensive medication; i.e.  $MMAS \geq 7$ . [19] For a  
40  
41 sensitivity analyses, we used a lower level of adherence with a cut-off of  $MMAS \geq 6$ .  
42  
43  
44  
45  
46

### 47 **Sample size**

48  
49 Achieved sample size was based on an estimated 30% prevalence of controlled BP among treated  
50  
51 hypertensive patients in Ethiopia [8,15] and a single proportion sample size calculation formula. The  
52  
53 total sample size was 984 (164 per hospital) with 0.80 power, 95% confidence interval, 3% margin of  
54  
55 error, and an estimated 10% none response rate, or incomplete/irretrievable patient records.  
56  
57  
58  
59  
60

### Statistical analyses

Descriptive statistics were used to summarize socio-demographic, disease characteristics of the study population, and nature and frequency of antihypertensive medications used. Multivariable logistic regression analyses were applied to investigate determinants for achieving target BP at current visit, and determinants for treatment intensification. Statistical significance was considered at  $p$  value  $< 0.05$ . Potential determinants with  $p < 0.2$  in bivariable analyses were included into the multivariable logistic model. Microsoft access 10 and SPSS version 22.0 statistical software was used for data entry and analyses respectively.

### Sensitivity analyses

We performed four sensitivity analyses. First, tighter BP targets at current visit (BP  $< 130/80$  mm Hg) were applied for those patients with diabetes mellitus (DM) and/or renal disease. Standard BP target (BP  $< 140/90$  mm Hg) was used for all others participants. Second, we performed a sensitivity analysis for the main outcome measure (controlled BP  $< 140/90$ ) using a different cut off for adherence (MMAS  $\geq 6$ ). Third (for controlled BP) and fourth (for treatment intensification) sensitivity analysis were similar with Table 2 and 3 with three modified determinants. Graded hypertension (prior BP) was performed according to the stages defined by the Ethiopian standard treatment guideline for hypertension: normal BP (systolic BP  $< 120$  and DBP  $< 80$  mm Hg), pre-hypertensive stage (systolic BP 120-139 or diastolic BP 80-89 mm Hg), stage-I hypertension (systolic BP 140-159 or diastolic BP 90-99 mm Hg), and stage-II hypertension (systolic BP  $\geq 160$  or diastolic BP  $\geq 100$  mm Hg).[21] These analysis also included the number of cardiometabolic comorbid illnesses as a proxy measure for more severely ill patients and age categorized in to five groups [22]. Patients with higher hypertension stages and multiple comorbid illness were hypothesized to be more difficult to treat.

### Ethics approval

This study was approved by Ethiopian Health Research Ethical Review Committees of (i) the College of Health Sciences, Mekelle University, (ii) St Paul's Hospital Millennium Medical College, and (iii) the Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University. All individual participants included in this study consented to participation.

For peer review only

## RESULTS

We were able to approach 968 patients at six public hospitals in Ethiopia. Seventy-one patients were excluded from our analyses; eight refused to participate, six were not hypertensive, and 57 patients had no retrievable records or incomplete records (missing BP at current visit), resulting in a study population of 897 patients (Figure 1). The majority of included patients (93%) reported to have come for their regular hypertension follow-up visit. The remaining 7% had (perceived) symptoms; uncontrolled hypertension or adverse events. The mean (SD) patient age was 57 (14) years, 63% of patients were female, most patients (65%) were married, and 64% had no formal education or only attended primary school. Almost all (94%) had never smoked, and nearly half (43%) consumed alcohol regularly or occasionally (Table 1). At the current visit, 35% study participants had at least one recorded comorbid illness, predominantly DM (Table 1).

**Table 1 Characteristics of ambulatory hypertensive patients at two visits, Ethiopia**

Characteristics	Current visit	Prior visit
<b>Demographics</b>		
Age (mean, SD), Year	57 (14)	
Female (n, %)	551 (63)	
Smoking [current smoker] (n, %)	57 (6)	
Alcohol use [regularly or sometimes] (n, %)	378 (43)	
Married (n, %)	567 (65)	
Education (n, %)		
University/college education	170 (20)	
Secondary education	141 (16)	
Primary or no formal education	557 (64)	
<b>Setting</b>		
Specialized hospitals: both from Addis Ababa (n, %)		
Tikur Anbessa Hospital	139 (16)	
St. Paul's Hospital	153 (17)	
General hospitals: all from Tigray, except Yekatit 12 from Addis Ababa (n, %)		
St. Mary Axum Hospital	139 (16)	
Mekelle Hospital	152 (17)	
Lemlem Karl Maychew Hospital	155 (17)	
Yekatit 12 Hospital	159 (18)	
<b>Disease characteristics</b>		
Blood pressure (BP)		
Systolic BP (Mean, SD)	139 (21)	144 (22)
Diastolic BP (Mean, SD)	84 (11)	85 (13)
Controlled BP (<140/90 mm Hg) (n, %)	335 (37)	231 (27)
Controlled BP (<130/80 mm Hg with DM &/or kidney diseases, #otherwise <140/90 mm Hg) (n, %)	268 (30)	202 (24)
Cardiometabolic comorbid illnesses (n, %)		
Diabetes Mellitus	227 (25)	198 (22)
Dyslipidemia	57 (6)	45 (5)
Renal diseases	25 (3)	23 (3)
Heart failure / myocardial infarction	72 (8)	60 (7)
<b>Antihypertensive treatment characteristics</b>		
Drug class (n, %)		
ACE inhibitors	503 (56)	494 (55)
Enalapril	499 (56)	492 (55)
Lisinopril or captopril	4 (0.4)	2 (0.2)
Beta blockers	167 (19)	166 (19)
Atenolol	148 (17)	147 (16)
Propranolol, metoprolol or carvedilol	19 (2)	19 (2)
Calcium channel blockers	449 (50)	439 (49)
Nifedipine	381 (43)	389 (43)
Amlodipine or felodipine	68 (8)	50 (6)
Diuretics †	498 (56)	486 (54)
Hydrochlorothiazide	428 (48)	421 (47)
Furosemide	76 (9)	71 (8)
Spironolactone	72 (8)	66 (7)
Others (methyldopa, nitrates or losartan)	19 (2)	13 (1)
Duration of therapy years (Median, interquartile rang)	4 (7)	
Visit schedule in months (mean, SD)	2.3 (2.0)	
Adherence (MMAS ≥ 7) (n, %)	355 (40)	
Therapy (n, %)		
Monotherapy	343 (38)	363 (41)
Multidrug therapy	550 (62)	521 (59)
Treatment intensified in patients with uncontrolled BP at current visit (n=540) * (n, %)	123 (23)	

Mono/Multidrug therapy is limited to antihypertensive medications. \*For 22 of 562 patients with uncontrolled BP at the current visit the medication history was not complete. Treatment intensification could thus only be calculated for 540 patients. † Some patients had more than one type of diuretics. #otherwise: hypertensive patients without DM or kidney disease.

1  
2  
3 Thirty-seven percent (n=335) of the participants had controlled BP at the current visit (Table 1).  
4  
5 Applying the stricter BP target for patients with DM and/or renal disease (BP<130/80 mm Hg), the  
6  
7 proportion of patients with controlled BP dropped to 27% (n=231).  
8  
9

10 Only, 23% of 540 patients with uncontrolled BP and complete medication history had their  
11  
12 treatment intensified (Table 1). For 22 (4%) of 562 patients with uncontrolled BP at the current visit,  
13  
14 the medication history was not complete, either the dose and/or administration frequency were  
15  
16 missing. The antihypertensive medication adherence rate (MMAS  $\geq$  7) was 40%, (Table 1), and 57%  
17  
18 for the lower cut off, MMAS  $\geq$  6 (Supplement Table 1).  
19  
20

21 Overall, angiotensin-converting-enzyme (ACE) inhibitors were the most commonly prescribed  
22  
23 group of drugs (n = 503), followed by diuretics (n = 498) (Table 1). Medication use was quite similar  
24  
25 on both visits. At the current visit 62% of included patients were prescribed a multidrug treatment  
26  
27 regimen and 45% patients took two antihypertensive agents (Supplement Table 2). Most (38 %) of  
28  
29 the 343 patients on monotherapy were prescribed diuretics (n=127).  
30  
31  
32

### 33 **Determinants of BP Control**

#### 34 *BP <140/90 mm Hg (primary analysis)*

35  
36 According to our multivariable logistic regression model (Table 2), factors significantly associated  
37  
38 with achieving target BP at the current visit were age (OR 0.99 [95% CI: 0.98; 1.00]), follow-up at  
39  
40 general hospitals (OR 1.89 [95% CI: 1.26; 2.83]), inadequately controlled BP at prior visit (OR 95% CI:  
41  
42 0.30 [0.21; 0.43]), longer treatment duration per year (OR 1.04 [95% CI: 1.01; 1.06]), and prescribed  
43  
44 diuretics (OR 0.68 [95% CI: 0.50; 0.94]).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2 Determinants of achieving target BP (BP < 140/90) at current visit in ambulatory hypertension patients**

Variables	Controlled BP		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), year	58 (13)	56 (15)	#0.99 [0.98; 1.00]	<b>*0.988 [0.976; 0.997]</b>	
Gender (n, %)	Male	219 (67)	109 (33)	Ref	
	Female	331 (60)	220 (40)	*1.34 [1.00; 1.78]	1.12 [0.80; 1.55]
Smoking (n, %)	No	514 (62)	312 (38)	Ref	
	Yes	37 (65)	20 (35)	0.89 [0.51; 1.56]	
Alcohol use (n, %)	No	310 (63)	184 (37)	Ref	
	Yes	232 (61)	146 (39)	1.06 [0.81; 1.40]	
Marital status (n, %)	Single	187 (60)	124 (40)	Ref	
	Married	359 (63)	208 (37)	0.87 [0.66; 1.16]	
Educational status (n, %)	College/University	110 (65)	60 (35)	Ref	
	Secondary	86 (61)	55 (39)	1.17 [0.74; 1.86]	
	Primary /not formal	345 (62)	212 (38)	1.13 [0.79; 1.61]	
Hospital type (n, %)	Specialized	199 (68)	93 (32)	Ref	
	General	363 (60)	242 (40)	*1.43 [1.06; 1.92]	<b>*1.89 [1.26; 2.83]</b>
<b>Disease characteristics (n, %)</b>					
Diabetes Mellitus	No	413 (62)	257 (38)	Ref	
	Yes	149 (66)	78 (34)	0.84 [0.61; 1.15]	
Dyslipidemia	No	523 (62)	317 (38)	Ref	
	Yes	39 (68)	18 (32)	0.76 [0.43; 1.35]	
Renal disease	No	542 (62)	330 (38)	Reference	
	Yes	20 (80)	5 (20)	#0.41 [0.15; 1.10]	0.58 [0.19; 1.71]
Heart failure/ MI	No	518 (63)	307 (37)	Ref	
	Yes	44 (61)	28 (39)	1.07 [0.66; 1.76]	
Controlled BP at prior visit	No	424 (68)	199 (32)	*0.37 [0.27; 0.51]	<b>*0.30 [0.21; 0.43]</b>
	Yes	102 (44)	129 (56)	Ref	
<b>Antihypertensive Treatment characteristics</b>					
Duration of therapy, years (mean, SD)	6.2 (6.4)	7.4 (8.3)	#1.02 [1.00; 1.04]	<b>*1.04 [1.01; 1.06]</b>	
Adherent (MMAS $\geq$ 7) (n, %)	No	319 (60)	212 (40)	Ref	
	Yes	233 (66)	122 (34)	#0.79 [0.60; 1.04]	0.80 [0.58; 1.09]
Revisit schedule in months (Mean, SD)	2.2 (1.4)	2.0 (1.2)	*0.89 [0.82 ;0.97]	0.91 [0.82; 1.02]	
Therapy at prior visit (n, %)	Monotherapy	225 (62)	138 (38)	Ref	
	Multidrug	326 (63)	195 (37)	0.98 [0.74; 1.29]	
<b>Antihypertensive medications at prior visit</b>					
ACE inhibitors (n, %)	No	259 (64)	144 (36)	Ref	
	Yes	303 (61)	191 (39)	1.13 [0.86; 1.49]	
Beta blockers (n, %)	No	472 (65)	259 (35)	Ref	
	Yes	90 (54)	76 (46)	*1.54 [1.09; 2.16]	1.42 [0.95; 2.10]
Calcium channel blockers (n, %)	No	290 (63)	168 (37)	Ref	
	Yes	272 (62)	167 (38)	1.06 [0.81 ;1.39]	
Diuretics (n, %)	No	243 (59)	168 (41)	Reference	
	Yes	319 (66)	167 (34)	*0.76 [0.58; 0.99]	<b>*0.68 [0.50; 0.94]</b>

Only patients with available data were included in the analyses, therefore numbers may sometimes differ from Table 1. Percentages are calculated per a row. Statistically significant values: \*p < 0.05 at 95% CI. Variables with #p < 0.20 or \*p < 0.05 in the bivariable model were included in the multivariable model. Mono/Multidrug therapy was for antihypertensive medications.

### Determinant of treatment intensification

The only statistically significant determinant for treatment intensification in the multivariable analyses was longer treatment duration (OR 1.05 [95% CI: 1.02; 1.09]), Table 3.

#### Sensitivity (secondary) analysis

*In our first sensitivity analyses, using BP <130/80 mm Hg for patients with DM and/or renal disease, and for all other patients <140/90 mm Hg as cut-offs, uncontrolled BP at the prior visit had a negative effect on achieving target BP at the current visit (OR 0.25 [95% CI: 0.17; 0.37]). Medications prescribed during the prior visit, except diuretics (OR 0.60 [95% CI: 0.40; 0.90]), were not significantly associated with achieving controlled BP at the current visit. Unlike the primary analyses, age, treatment duration, and hospital type did not show statistically significant effects on current visit BP status (Supplement Table 3).*

In the sensitivity analyses for BP control (supplement Table 4) and treatment intensification (supplement Table 5), the results were mostly similar with the main analysis (Table 2 and 3) respectively. As expected, more severe hypertension stage was associated with more difficulty to achieve target BP: stage-II hypertension [(OR 0.17 [95% CI 0.09;0.35]), and stage-I hypertension [(OR 0.34 [95% CI 0.17;0.67]). However, number of comorbid illness was not significant determinants. In case of age, older age groups were less likely to achieve target BP than youngest age group (<35 years): 55-64 years old (OR 0.41 [95% CI 0.20; 0.83]) and ≥ 65 years old (OR 0.46 [95 CI: 0.22;0.93]). Supplementary analysis for treatment intensification (Supplement Table 5), gave similar results with main analysis on Table 3, where only duration of therapy was positive significant determinant (OR 1.05 [95% CI: 1.02; 1.08]) of treatment intensification.



**Table 3 Treatment intensification determinants for ambulatory hypertension patients with uncontrolled BP at current visit**

Variables	Treatment intensified		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), Year	57 (13)	60 (13)	#1.02 [1.00; 1.03]	1.02 [1.00; 1.04]	
Gender (n, %)	Male	167 (80)	41 (20)	Ref	
	Female	241 (75)	80 (25)	#1.35 [0.88; 2.07]	1.47 [0.91; 2.37]
Smoking (n, %)	No	383 (77)	113 (23)	Ref	
	Yes	27 (79)	7 (21)	0.88 [0.37; 2.07]	
Alcohol use (n, %)	No	225 (76)	73 (25)	Ref	
	Yes	180 (80)	44 (20)	0.75 [0.49; 1.15]	
Marital status (n, %)	Single	138 (77)	42 (23)	Ref	
	Married	269 (78)	76 (22)	0.93 [0.60; 1.43]	
Educational status (n, %)	College/University	82 (78)	23 (22)	Ref	
	Secondary	58 (70)	25 (30)	1.54 [0.80; 2.97]	
	Primary/not formal education	262 (79)	70 (21)	0.95 [0.56; 1.62]	
Hospital type (n, %)	Specialized	137 (73)	51 (27)	Ref	
	General	280 (80)	72 (21)	#0.69 [0.46; 1.04]	0.83 [0.51; 1.37]
<b>Disease characteristics (n, %)</b>					
Diabetes Mellitus at current visit	No	311 (79)	84 (21)	Ref	
	Yes	106 (73)	39 (27)	#1.36 [0.88; 2.11]	1.10 [0.67; 1.81]
Dyslipidemia at current visit	No	388 (77)	113 (23)	Reference	
	Yes	29 (74)	10 (26)	1.19 [0.56; 2.50]	
Renal disease at current visit	No	403 (77)	118 (23)	Ref	
	Yes	14 (74)	5 (26)	1.22 [0.43; 3.45]	
Heart Failure / MI at current visit	No	384 (77)	112 (23)	Ref	
	Yes	33 (75)	11 (25)	1.14 [0.56; 2.33]	
Controlled BP at prior visit	No	312 (77)	96 (24)	#1.50 [0.85; 2.66]	1.38 [0.76; 2.50]
	Yes	83 (83)	17 (17)	Ref	
<b>Antihypertensive treatment characteristics</b>					
Duration of therapy yrs (mean SD)		5.7 (4.1)	8.1 (7.4)	*1.05 [1.02; 1.08]	*1.05 [1.02; 1.09]
Adherence (MMAS $\geq$ 7) (n, %)	No	232 (76)	73 (24)	Ref	
	Yes	178 (78)	49 (22)	0.88 [0.58; 1.32]	
Therapy at prior visit (n, %)	Monotherapy	168 (76)	53 (24)	Ref	
	Multidrug therapy	249 (78)	70 (22)	0.89 [0.59; 1.34]	

Statistically significant values: \* $p < 0.05$  at 95% CI. Variable with # $p < 0.2$  or \* $p < 0.05$  in the bivariable model were included in the multivariable model. Percentages are calculated per row. Treatment intensification was calculated for 540 patients who had complete medication history (including dose and frequency) on both visits and uncontrolled BP at current visit.

## DISCUSSION

In this study, nearly two-thirds of patients on antihypertensive medication had uncontrolled BP. Drugs were prescribed from four antihypertensive drug classes, ACE-inhibitors, diuretics, CCBs, and BBs. Generally, a single specific agent (over 90%) was prescribed within a class, enalapril, hydrochlorothiazide, nifedipine, and atenolol respectively. Age of patients, uncontrolled BP at prior visit, and a treatment regimen containing diuretics contributed to poorer BP control. Follow-up in a general hospital as compared to a specialized hospital, and longer treatment duration were associated with a better BP control. Duration of therapy on antihypertensive medication was the only, albeit modestly, significant contributing factor of treatment intensification (also for control BP).

Most other studies in Africa, 41 out of 44, showed a lower proportion of patients with controlled BP (these studies reported levels of control ranging from <1% to 33%) than our study.[8] The reported wide variation could be explained by population differences and variation in study set-ups. The level of BP control in our study was in between that reported in two studies performed in a Southern Ethiopia hospital.[16,23] Gudina *et al* studied the prevalence of hypertension among patients visiting a hospital for any reason, of patients with known hypertension 44% were controlled.[23] The study by Asgedom *et al* was more similar to ours with 50% of patients visiting an outpatient hypertension clinic who had been treated for at least 12 months in the study hospital.[16] The longer duration of treatment in this latter study compared to ours perhaps may explain the better level of control, considering that duration of therapy was a significant determinant in our study for BP control.

In comparison with studies in western countries, the percentage of patients with adequately controlled BP, and those who received treatment intensification was lower in our study than in North American countries, but similar to some European countries.[24,25] These differences may be explained in part by different recommendations between national guidelines. However, as reported

1  
2  
3 elsewhere, it is not only differences between guidelines, but also how much effort countries put in  
4  
5 implementation of these recommendations.[25] While the Ethiopian guideline is similar to the USA  
6  
7 guidelines,[21,24] possible differences in implementation, due to African factors including resource  
8  
9 limitations, low priority for communicable diseases, and healthcare providers' behavior and skills  
10  
11 may in part explain the low level of BP control.[26] However, comparing our results with population  
12  
13 based studies in western countries or those in other part of Africa should be done with caution as we  
14  
15 investigated regional Ethiopian hypertensive population treated at a hospital setting.  
16  
17

18  
19 In our study, one of the determinants for achieving target BP was the healthcare setting. Patients  
20  
21 who are referred to specialized hospitals may be more complex – in terms of comorbidities or  
22  
23 severity of hypertension. Hence, it is surprising that patients in these hospitals are more likely to  
24  
25 have inadequately controlled BP. Younger age was another significant determinant for achieving  
26  
27 target BP. Prescribers in our study may have accepted higher BP in older patients, possibly because  
28  
29 of tolerability or perceived lack of need for tight BP control. Recent evidence, however, suggests that  
30  
31 “the lower is the better” also in older patients.[27,28] Nevertheless, guidelines lack consistency on  
32  
33 BP targets for elderly,[29] especially when patients are frail and doctors may not aim for tight BP  
34  
35 control. Another determinant of BP control was the type of medication prescribed. Most of our study  
36  
37 participants received diuretics, the first line antihypertensive agents. We have no data in which order  
38  
39 medication was initiated; therefore, we can only speculate why treatment regimens containing these  
40  
41 drugs did not show better BP control. Since three-quarters of diuretics-containing regimens in our  
42  
43 study existed of two drugs only (Supplement Table 2), patients may need additional therapy.  
44  
45  
46  
47  
48

49  
50 Only one fifth of patients with uncontrolled BP at the current visit had their treatment intensified.  
51  
52 Longer treatment duration was the only statistically significant determinant for intensification.  
53  
54 Possibly, it took a while before prescribers would intensify treatment. Ultimately, the lack of BP  
55  
56 control at the prior visit was the strongest predictor of patients not having controlled BP at current  
57  
58  
59  
60

1  
2  
3 visit. This seems to suggest some level of 'clinical inertia', where doctors are slow to respond to  
4  
5 clinical parameters indicating a need to step up therapy. However, it may also be explained by true  
6  
7 therapy resistant hypertension (although only 17% of patients received three or more  
8  
9 antihypertensive agents at the prior visit).[30-33] Moreover, prescribers may not intensify treatment  
10  
11 if they suspect that increased BP levels may be related to a suspected or reported poor compliance  
12  
13 for a particular patient. (Poor) medication adherence is known as an important determinant for  
14  
15 controlling hypertension.[34] The level of adherence we observed (40% and 57% for MMAS-8 with a  
16  
17 cut-off at  $> 6$  and  $\geq 6$  respectively) was close to that reported by Asgedom *et al* (35% and 61%  
18  
19 respectively).[16] Two other Ethiopian studies reported low levels of adherence although more  
20  
21 difficult to compare as they used a 4-point MMAS.[35, 36] Surprisingly, the level of adherence was  
22  
23 not associated with BP control in our main and sensitivity analyses (Supplement Table 1). Similarly in  
24  
25 the study by Asgedom *et al*, a hospital-based study in Southern Ethiopia, no relation with adherence  
26  
27 and BP control was observed.[16] Self-reported medication adherence may be overestimated and  
28  
29 therefore lead to bias.

30  
31  
32  
33  
34  
35  
36 An interesting finding was that more hypertensive women than men were included in our study,  
37  
38 and that so few patients smoked. One reason why more women were included could be that  
39  
40 hypertension is more prevalent in Ethiopian females as suggested in a recent community-based  
41  
42 study evaluating prevalence of hypertension in Ethiopia.[13] Another explanation may be that  
43  
44 women with hypertension seek care more regularly than men. However, a meta-analysis including  
45  
46 hospital-based studies showed a higher prevalence of hypertension for males.[15] Another recent  
47  
48 hospital-based study also indicated a higher prevalence of males with hypertension.[16] We  
49  
50 observed that women were not more likely than men to have controlled BP or their treatment  
51  
52 intensified.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Poor hypertension control should be addressed in a holistic approach that includes life style  
4 modification and management of comorbid illnesses. Our study was largely performed in urban  
5 areas, which have the highest prevalence of hypertension in Ethiopia, which is attributed to adoption  
6 of a Western life-style.[15] Still, our patient population looks very different from that in European or  
7 USA studies; i.e. with few smokers and few patients with (known) cardiometabolic comorbidities.  
8  
9

### 14 **Strengths and limitations**

15  
16 As far as we are aware, this was the first study of its kind in Ethiopia covering a relatively diverse  
17 population. Our data included patients from hypertension outpatient clinics of six public hospitals in  
18 the capital city and northern region of Ethiopia.  
19  
20  
21  
22

23  
24 A limitation of our study was the validity of the BP measure used. We analysed BP measurements  
25 as recorded in patients' medical records that reflected actual clinical practice, but may be subject to  
26 recording and measurement error. It is not clear how prescribers considered measurement variability  
27 or if any attempt was made to avoid 'white-coat' hypertension, e.g. by repeating BP measurement.  
28  
29 Still, many observational studies use medical records – with data collected in routine practice - as a  
30 data source. Future studies may consider using standardized assessment of BP evaluation. Another  
31 limitation is that medical records did not include extensive or well-structured patient information.  
32  
33 For example, comorbidities may be underreported. For this reason, we limited evaluated  
34 comorbidities to cardiometabolic diseases as these are relevant to hypertension prognosis and  
35 treatment and are more likely to have been recorded in the charts. This study focused on public  
36 secondary and specialized hospitals; therefore the result may not be generalizable to other settings  
37 such as private practices and primary health care centers. Differences in socioeconomic status did  
38 not seem related with type of drug prescribed. This may have affected redeeming prescriptions at  
39 the pharmacy but we did not record that information. Nevertheless, educational status – a proxy for  
40 socioeconomic status – in our study population was not related to BP control.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSION

Nearly two-thirds of patients on antihypertensive medication did not achieve target BP during routine clinical follow-up, and only a quarter of these patients with uncontrolled BP received treatment intensification. To improve care for patients visiting Ethiopian hospital hypertension clinics, focus should be on older patients and interventions may be needed for specialized centers.

## Acknowledgments

Authors wish to thank study participants, data collectors, and study hospital administrators who contributed to this study.

## Contribution

D.F. Berhe, K. Taxis and P. Mol designed and performed the research, analyzed, and interpreted the data. Flora M Haaijer-Ruskamp, Afework Mulugeta, and Yewondwossen Tadesse Mengistu designed the study. All authors participated in writing the manuscript, also read and approved the final version.

**Conflict of Interest:** There are no competing interests to declare.

## Funding

The study was part of a PhD project to the first author funded by Netherlands Organization for International Cooperation in Higher Education (NUFFIC).

## Data sharing statement

No additional data are available for this specific study.

## REFERENCES

- (1) World Health Organization. A global brief on hypertension: Silent killer, global public health crisis. 2013. Available from [http://apps.who.int/iris/bitstream/10665/79059/1/WHO\\_DCO\\_WHD\\_2013.2\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf) [accessed on 2016-05-17]
- (2) Fuchs FD. Why do black Americans have higher prevalence of hypertension? an enigma still unsolved. *Hypertension* 2011;57:379-80.
- (3) Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and  $\beta$ -adrenergic blockers? A systematic review. *BMC med* 2013;11:1.
- (4) Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. *Circulation* 2005;112:3562-3568.
- (5) Sagnella G. Why is plasma renin activity lower in populations of African origin? *J Hum Hypertens* 2001;15:17-25.
- (6) Dennison CR, Peer N, Steyn K, *et al.* Determinants of hypertension care and control among peri-urban Black South Africans: The HiHi study. *Ethn Dis* 2007;17:484-91.
- (7) James PA, Oparil S, Carter BL, *et al.* 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014;311:507-20.
- (8) Kayima J, Wanyenze RK, Katamba A, *et al.* Hypertension awareness, treatment and control in Africa: a systematic review. *BMC Cardiovasc Disord* 2013;13:54.
- (9) Kessler CS, Joudeh Y. Evaluation and treatment of severe asymptomatic hypertension. *Am Fam Physician* 2010;81:470-6.
- (10) van de Vijver S, Akinyi H, Oti S, *et al.* Status report on hypertension in Africa-consultative review for the 6th Session of the African Union Conference of Ministers of Health on NCD's. *Pan Afr Med J* 2013;16:38.
- (11) Naicker S, Plange-Rhule J, Tutt RC, *et al.* Shortage of healthcare workers in developing countries-Africa. *Ethn Dis* 2009;19 Suppl 1:S160-4.
- (12) Mancia G, Fagard R, Narkiewicz K, *et al.* 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Blood Press* 2013;22:193-278.
- (13) Abebe SM, Berhane Y, Worku A, *et al.* Prevalence and associated factors of hypertension: a cross sectional community based study in Northwest Ethiopia. *PLoS One* 2015;10:e0125210.

- 1  
2  
3 (14) Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa:  
4 a systematic analysis. *PLoS One* 2014;9:e104300.  
5  
6 (15) Kibret KT, Mesfin YM. Prevalence of hypertension in Ethiopia: a systematic meta-analysis. *Public*  
7 *Health Reviews* 2015;36:14.  
8  
9 (16) Asgedom SW, Gudina EK, Desse TA. Assessment of Blood Pressure Control among Hypertensive  
10 Patients in Southwest Ethiopia. *PLoS One* 2016;11:e0166432.  
11  
12 (17) Shukrala F, Gabriel T. Assessment of prescribing, dispensing, and patient use pattern of  
13 antihypertensive drugs for patients attending outpatient department of Hiwot Fana Specialized  
14 University Hospital, Harar, Eastern Ethiopia. *Drug Des Devel Ther* 2015; 9:519-23.  
15  
16 (18) Federal Democratic Republic of Ethiopia Ministry of Health. Health sector transformation plan  
17 (HSTP)-2015/16 – 2019/20. Ethiopia Ministry of Health, 2015, p142. Available from  
18 [http://www.moh.gov.et/documents/26765/0/Health+Sector+Transformation+Plan/5542a23a-9bc7-](http://www.moh.gov.et/documents/26765/0/Health+Sector+Transformation+Plan/5542a23a-9bc7-46a2-8c1f-8b32c2603208?version=1.0)  
19 [46a2-8c1f-8b32c2603208?version=1.0](http://www.moh.gov.et/documents/26765/0/Health+Sector+Transformation+Plan/5542a23a-9bc7-46a2-8c1f-8b32c2603208?version=1.0) [accessed on 2017-03-15]  
20  
21 (19) Lee GK, Wang HH, Liu KQ, *et al.* Determinants of medication adherence to antihypertensive  
22 medications among a Chinese population using Morisky Medication Adherence Scale. *PLoS One*  
23 2013;8:e62775.  
24  
25 (20) Morisky DE, Ang A, Krousel-Wood M, *et al.* Predictive validity of a medication adherence  
26 measure in an outpatient setting. *J Clin Hypertens* 2008;10:348-54.  
27  
28 (21) Beaton DE, Bombardier C, Guillemin F, *et al.* Guidelines for the process of cross-cultural  
29 adaptation of self-report measures. *Spine* 2000;25:3186-91.  
30  
31 (22) FMHACA. Hypertension: Standard Treatment Guidelines for General Hospitals, Ethiopia. Third  
32 Edition ed.: Food, Medicine and Health Care Administration and Control Authority(FMHACA); 2014.  
33 p. 47-53.  
34  
35 (23) Gudina EK, Michael Y, Assegid S. Prevalence of hypertension and its risk factors in southwest  
36 Ethiopia: a hospital-based cross-sectional survey. *Integr Blood Press Control* 2013;6:111-117.  
37  
38 (24) Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment  
39 intensification, and control in Western Europe and the United States. *Arch Intern Med* 2007;167:141-  
40 7.  
41  
42 (25) Wolf-Maier K, Cooper RS, Kramer H, *et al.* Hypertension treatment and control in five European  
43 countries, Canada, and the United States. *Hypertension* 2004;43:10-7.  
44  
45 (26) Nulu S, Aronow WS, Frishman WH. Hypertension in Sub-Saharan Africa: A Contextual View of  
46 Patterns of Disease, Best Management, and Systems Issues. *Cardiol Rev* 2016;24:30-40.  
47  
48 (27) SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control.  
49 *N Engl J Med* 2015;373:2103-16.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 (28) Perkovic V, Rodgers A. Redefining blood-pressure targets - SPRINT starts the marathon. *N Engl J*  
4 *Med* 2015;373:2175-78.

5  
6 (29) Alhawassi TM, Krass I, Pont LG. Hypertension in older persons: A systematic review of national  
7 and international treatment guidelines. *J Clin Hypertens* 2015;17:486-92.

8  
9 (30) Phillips LS, Branch WT, Cook CB, *et al.* Clinical inertia. *Ann Intern Med* 2001;135:825-34.

10  
11 (31) Moser M. Physician or clinical inertia: what is it? Is it really a problem? And what can be done  
12 about it? *J Clin Hypertens* 2009;11:1-4.

13  
14 (32) Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of  
15 resistant hypertension in treated hypertensive populations. *Am J Hypertens* 2015;28:355-61.

16  
17 (33) Nansseu JR, Noubiap JJ, Mengnjo MK, *et al.* The highly neglected burden of resistant  
18 hypertension in Africa: a systematic review and meta-analysis. *BMJ Open* 2016;6:e011452.

19  
20 (34) Corrao G, Parodi A, Nicotra F, *et al.* Better compliance to antihypertensive medications reduces  
21 cardiovascular risk. *J Hypertens* 2011;29:610-8.

22  
23 (35) Ambaw AD, Alemie GA, Mengesha ZB. Adherence to antihypertensive treatment and associated  
24 factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. *BMC*  
25 *Public Health* 2012;12:282.

26  
27 (36) Hareri HA, Abebe M, Asefaw T. Assessments of adherence to hypertension managements and its  
28 influencing factors among hypertensive patients attending black lion hospital chronic follow up unit,  
29 Addis Ababa, Ethiopia-a cross-sectional study. *International Journal of Pharmaceutical Sciences and*  
30 *Research* 2013;4:1086.

### 31 32 33 34 35 36 37 38 39 **Figure legend**

40  
41 Figure 1 Flow chart for case inclusion for analysis  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1




Figure 1 Flow chart for case inclusion for analysis

194x198mm (300 x 300 DPI)



1  
2  
3 **HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS:**

4  
5 **A RETROSPECTIVE COHORT STUDY IN EHTIOPIA**

6  
7  
8  
9 **Supplement Table 1 Determinants of achieving target BP (BP < 140/90) at index visit ambulatory hypertension patients (sensitivity analysis with adherence definition of MMAS ≥ 6)**

Variables	Controlled BP		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), year	58 (13)	56 (15)	#0.99 [0.98; 1.00]	*0.99 [0.98; 1.00]	
Gender (n, %)	Male	219 (67)	109 (33)	Ref	
	Female	331 (60)	220 (40)	#1.34 [1.00; 1.78]	1.12 [0.81; 1.55]
Hospital type (n, %)	Specialized	199 (68)	93 (32)	Ref	
	General	363 (60)	242 (40)	*1.43 [1.06; 1.92]	*1.88 [1.25; 2.81]
<b>Disease characteristics at index visit (n, %)</b>					
Renal disease	No	542 (62)	330 (38)	Reference	
	Yes	20 (80)	5 (20)	#0.41 [0.15; 1.10]	0.60 [0.20; 1.79]
Controlled BP at prior visit	No	424 (68)	199 (32)	*0.37 [0.27; 0.51]	*0.30 [0.21; 0.43]
	Yes	102 (44)	129 (56)	Ref	
<b>Antihypertensive Treatment characteristics</b>					
Duration of therapy, years (mean, SD)	6.2(6.4)	7.4 (8.3)	#1.02 [1.00; 1.04]	*1.04 [1.02; 1.06]	
Adherent (MMAS ≥ 6) (n, %)	No	237 (63)	140 (37)	Ref	
	Yes	315 (62)	194 (38)	1.04 [0.79; 1.37]	1.14 [0.83; 1.56]
Revisit schedule in months (Mean,	2.2 (1.4)	2.0 (1.2)	*0.89 [0.82 ;0.97]	0.91 [0.82; 1.02]	
Beta blockers (n, %)	No	472 (65)	259 (35)	Ref	
	Yes	90 (54)	76 (46)	*1.54 [1.09; 2.16]	1.45 [0.98; 2.15]
Diuretics (n, %)	No	243 (59)	168 (41)	Reference	
	Yes	319 (66)	167 (34)	*0.76 [0.58; 0.99]	*0.68 [0.50; 0.94]

Variables with #p < 0.20 or \*p < 0.05 in the bivariable model were included in this multivariable model (sensitivity analysis).

**Supplement Table 2 Prescribed antihypertensive medication(s) per patient**

Drug prescribed per case	At Index visit (n <sup>*</sup> =887), %	At Prior visit (n <sup>*</sup> =882), %
D (Diuretics)	14.3	15.0
C (CCBs)	13.0	13.7
A (ACE inhibitors)	9.9	11.0
B (BBs)	0.8	1.4
DC	9.4	8.6
DA	17.0	16.6
CA	11.5	10.2
AB	2.6	2.4
CB	2.4	2.7
DB	2.0	1.5
DCB	1.5	1.1
DCA	6.1	6.1
ACB	3.7	3.5
DAB	2.7	2.5
DABC	3.2	3.7

CCBs, calcium channel blockers; ACE, Angiotensinogen Converting Enzyme; BBs; Beta Blockers

\*The table did not include rarely used medication categories. These drugs were methyldopa, losartan, hydralazine, and nitrates and in combination with others or as a monotherapy.

**Supplement Table 3 Sensitivity analyses: determinants for controlled hypertension at alternative BP target (BP <130/80 mm Hg) for patients with DM and/or renal disease, and all other patients BP <140/90 mm Hg)**

Variables	Controlled BP		Bivariable OR [95% CI]	Multivariable OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD)	58 (13)	56 (15)	#0.99 [0.98; 1.00]	0.99 [0.98; 1.00]	
Gender (n, %)	Male	244 (74)	84 (26)	Ref	
	Female	373 (68)	178 (32)	*1.39 [1.02; 1.88]	1.30 [0.87; 1.95]
Smoking (n, %)	No	572 (69)	254 (31)	Ref	
	Yes	45 (79)	12 (21)	#0.60 [0.31; 1.16]	1.05 [0.50; 2.24]
Alcohol use (n, %)	No	354 (72)	140 (28)	Ref	
	Yes	254 (67)	124 (33)	#1.23 [0.92; 1.65]	1.54 [1.07; 2.21]
Marital status (n, %)	Single	207 (67)	104 (33)	Ref	
	Married	406 (72)	161 (28)	#0.79 [0.59; 1.06]	0.82 [0.56; 1.18]
Educational status (n, %)	College/University	123 (72)	47 (28)	Ref	
	Secondary	103 (73)	38 (27)	1.21 [0.83; 1.77]	
	Primary /not formal	381 (68)	176 (32)	0.97 [0.59; 1.59]	
Hospital type (n, %)	Specialized	217 (74)	75 (26)	Ref	
	General	412 (68)	193 (32)	1.36 [0.99; 1.85]	1.17 [0.75; 1.82]
<b>Disease characteristics (n, %)</b>					
Dyslipidemia at index visit	No	583 (69)	257(31)	Ref	
	Yes	46 (81)	11 (19)	#0.54 [0.28; 1.06]	0.47 [0.20; 1.10]
Heart Failure / MI at index visit	No	578 (70)	247 (30)	Ref	
	Yes	51 (71)	21 (29)	0.96 [0.57; 1.64]	
Controlled BP at prior visit	No	501 (77)	151 (23)	*0.25 [0.18; 0.35]	*0.25 [0.17; 0.37]
	Yes	92 (46)	110 (55)	Ref	
<b>Antihypertensive treatment characteristics</b>					
Duration of therapy years (mean, SD)	7.0 (7.3)	5.8 (6.9)	#0.98 [0.96; 1.00]	0.99 [0.97; 1.02]	
Adherence (MMAS-8 ≥ 7) (n, %)	No	373 (70)	158 (29)	Ref	
	Yes	246 (69)	109 (31)	1.04 [0.78; 1.40]	
Revisit schedule in months (Mean, SD)	2.4 (2.1)	2.0 (1.2)	*0.88 [0.81; 0.97]	0.94 [0.84; 1.06]	
Therapy at prior visit (n, %)	Monotherapy	240 (66)	123 (34)	Ref	
	Multidrug therapy	378 (73)	143 (27)	*0.74 [0.55; 0.99]	1.02 [0.69; 1.51]
<b>Antihypertensive medications at prior visit</b>					
ACE inhibitors (n, %)	No	274 (68)	129 (32)	Ref	
	Yes	355 (72)	139 (28)	0.83 [0.62; 1.11]	
Beta blockers (n, %)	No	511 (70)	220 (30)	Ref	
	Yes	118 (71)	48 (29)	0.95 [0.65; 1.37]	
Calcium channel blockers (n, %)	No	312 (68)	146 (32)	Ref	
	Yes	317 (72)	122 (28)	#0.82 [0.62; 1.10]	0.88 [0.59; 1.31]
Diuretics (n, %)	No	276 (67)	135 (33)	Ref	
	Yes	353 (73)	133 (27)	#0.77 [0.58; 1.03]	*0.60 [0.40; 0.90]

**Supplement Table 4: Determinants of achieving target BP (BP < 140/90) at index visit in ambulatory hypertension patients**

Variables	Odds ratio at 95% CI	
	Bivariable estimates	Multivariable estimate
<b>Demographics</b>		
Age [year]		
< 35	Ref	
35-44	0.56 [0.27; 1.18]	0.51 [0.24; 1.10]
45-54	0.51 [0.25; 1.03]	0.53 [0.26; 1.10]
55-64	0.40 [0.20; 0.80]	0.41 [0.20; 0.83]
≥ 65	0.50 [0.25; 0.99]	0.46 [0.22; 0.93]
Gender		
Male	Ref	
Female	*1.34 [1.00; 1.78]	1.15 [0.83; 1.61]
Smoking		
No	Ref	
Yes	0.89 [0.51; 1.56]	
Alcohol use		
No	Ref	
Yes	1.06 [0.81; 1.40]	
Marital status		
Single	Ref	
Married	0.87 [0.66; 1.16]	
Educational status		
College/University	Ref	
Secondary	1.17 [0.74; 1.86]	
Primary /not formal	1.13 [0.79; 1.61]	
Hospital type		
Specialized	Ref	
General	*1.43 [1.06; 1.92]	*2.05 [1.36; 0.09]
<b>Disease characteristics</b>		
Number of cardiometabolic comorbid illnesses	0.86 [0.69; 1.06]	0.84 [0.64; 1.11]
Hypertension severity at prior visit		
Normal BP (systolic BP < 120 and diastolic BP < 80 mm Hg)	Ref	
Pre-hypertensive stage (systolic BP 120-139 or diastolic BP 80-89 mm Hg)	0.83 [0.45; 1.53]	0.80 [0.40; .62]
Stage I hypertension (systolic BP 140-159 or diastolic BP 90-99 mm Hg)	*0.40 [0.21; 0.72]	*0.34 [0.17; .67]
Stage II hypertension (systolic BP ≥ 160 or diastolic BP ≥ 100 mm Hg)	*0.25 [0.14; 0.46]	*0.17 [0.09; .35]
<b>Antihypertensive Treatment characteristics</b>		
Duration of therapy, years (mean, SD)	#1.02 [1.00; 1.04]	*1.04 [1.02; .07]
Adherent (MMAS ≥ 7)		
No	Ref	
Yes	#0.79 [0.60; 1.04]	0.75 [0.54; 1.04]
Revisit schedule in months (Mean, SD)	*0.89 [0.82 ;0.97]	0.93 [0.83; 1.04]
Therapy at prior visit		
Monotherapy	Ref	
Multidrug therapy	0.98 [0.74; 1.29]	
Antihypertensive medications at prior visit		
ACE inhibitors		
No	Ref	
Yes	1.13 [0.86; 1.49]	
Beta blockers		
No	Ref	
Yes	*1.54 [1.09; 2.16]	*1.63 [1.08; .45]
Calcium channel blockers		
No	Ref	
Yes	1.06 [0.81 ;1.39]	
Diuretics		
No	Reference	
Yes	*0.76 [0.58; 0.99]	*0.68 [0.49; 0.94]

Difference with the main analysis (Table 2): Age categorical, prior BP based on severity, and comorbid illness count included.

**Supplement Table 5 Treatment intensification determinants for ambulatory hypertension patients with uncontrolled BP at index visit**

Variables		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]
<b>Demographics</b>			
Age, Year	< 35	Ref	
	35-44	1.53 [0.39; 5.99]	1.25 [0.31; 5.02]
	45-54	1.45 [0.39; 5.38]	1.08 [0.28; 4.10]
	55-64	1.95 [0.55; 6.96]	1.20 [0.33; 5.49]
	≥ 65	2.03 [0.57; 7.26]	1.49 [0.41; 2.22]
Gender	Male	Ref	
	Female	#1.35 [0.88; 2.07]	1.40 [0.86; 1.29]
Smoking	No	Ref	
	Yes	0.88 [0.37; 2.07]	
Alcohol use	No	Ref	
	Yes	0.75 [0.49; 1.15]	
Marital status	Single	Ref	
	Married	0.93 [0.60; 1.43]	
Educational status	College/University	Ref	
	Secondary	1.54 [0.80; 2.97]	
	Primary /no formal education	0.95 [0.56; 1.62]	
Hospital type	Specialized	Ref	
	General	#0.68 [0.43; 1.06]	0.78 [0.48 1.29]
<b>Disease characteristics</b>			
Cardiometabolic comorbid illness at current visit		#1.15 [0.86; 1.52]	1.04 [0.74; 1.45]
Hypertension severity at prior visit			
Normal BP (systolic BP < 120 and diastolic BP < 80 mm Hg)		Ref	
Pre-hypertensive stage (systolic BP 120-139 or diastolic BP 80-89)		0.65 [0.20; 2.07]	
Stage-I hypertension (systolic BP 140-159 or diastolic BP 90-99 mm Hg)		0.93 [0.32; 2.68]	
Stage-II hypertension (systolic BP ≥ 160 or diastolic BP ≥ 100 mm Hg)		1.15 [0.40; 3.26]	
<b>Antihypertensive treatment characteristics</b>			
Duration of therapy years (mean SD)		*1.05 [1.02; 1.08]	*1.05 [1.02; 1.08]
Adherence (MMAS ≥ 7)	No	Ref	
	Yes	0.88 [0.58; 1.32]	
Therapy at prior visit	Monotherapy	Ref	
	Multidrug therapy	0.89 [0.59; 1.34]	

Difference with the main analysis (table 3): Age grouped, prior BP based on severity, and comorbid illness count included.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	12
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	9
<b>Results</b>			



Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11, also on Figure 1
		(b) Give reasons for non-participation at each stage	11 also on Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12
		(b) Indicate number of participants with missing data for each variable of interest	12
		(c) Summarise follow-up time (eg, average and total amount)	12 (visit schedule)
Outcome data	15*	Report numbers of outcome events or summary measures over time	12 and 13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14 and 16 ( Table 2 and 3)
		(b) Report category boundaries when continuous variables were categorized	12 ( Table 1)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplement Tables 1-5)
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	17
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18 and 20
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A RETROSPECTIVE COHORT STUDY IN ETHIOPIA

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015743.R2
Article Type:	Research
Date Submitted by the Author:	09-Jun-2017
Complete List of Authors:	Berhe, Derbew Fikadu; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology; Mekelle University, Department of Pharmacy Taxis, Katja; University of Groningen, Department of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics Haaijer-Ruskamp, Flora; University of Groningen, University Medical Center, Department of Clinical Pharmacy and Pharmacology Mulugeta, Afework; Mekelle University, School of Public Health Mengistu, Yewondwossen Tadesse; Addis Ababa University, College of Health Sciences, School of Medicine, Department of Internal Medicine Mol, Peter; University Medical Center Groningen, University Medical Center, Department of Clinical Pharmacy and Pharmacology
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics, Public health
Keywords:	Hypertension < CARDIOLOGY, Adult cardiology < CARDIOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

1  
2  
3 1 **HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS: A**  
4  
5 2 **RETROSPECTIVE COHORT STUDY IN ETHIOPIA**

6  
7 3 **Short title: hypertension treatment practices and determinants**  
8  
9  
10 4

11  
12 5 Derbew Fikadu Berhe<sup>1,2</sup>, Katja Taxis<sup>3</sup>, Flora M Haaijer-Ruskamp<sup>1</sup>, Afework Mulugeta<sup>4</sup>, Yewondwossen

13  
14 6 Tadesse Mengistu<sup>5</sup>, Peter GM Mol<sup>1</sup>  
15

16  
17 7 <sup>1</sup>Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical

18  
19 8 Center Groningen, The Netherlands  
20

21  
22 9 <sup>2</sup>Department of Pharmacy, College of Health Sciences, Mekelle University, Ethiopia  
23

24  
25 10 <sup>3</sup>Department of Pharmacy, Unit Pharmacotherapy, -epidemiology & economics, University of

26  
27 11 Groningen, The Netherlands  
28

29  
30 12 <sup>4</sup>School of Public Health, College of Health Sciences, Mekelle University, Ethiopia  
31

32  
33 13 <sup>5</sup>Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa

34  
35 14 University, Ethiopia  
36

37  
38 15

39  
40 16 Corresponding author:

41  
42 17 Peter GM Mol

43  
44 18 University Medical Center Groningen, UMCG

45  
46 19 Department of Clinical Pharmacy and Pharmacology, EB70

47  
48 20 Hanzeplein 1, PO BOX 30001, 9700 RB Groningen

49  
50 21 The Netherlands

51  
52 22 + 31 (0)50 363 8313, Fax. +31 (0)50 363 2812

53  
54 23 Email : p.g.m.mol@umcg.nl  
55

56  
57 24

58  
59 25 Word count: 4,102

60  
26 Number of tables: 3, supplement tables: 6, and, Figure: 1

27 References: 36

1  
2  
3 **1 ABSTRACT**  
4

5 **2 Objectives:** We examined determinants of achieving blood pressure control in hypertensive patients  
6  
7  
8 **3** and of treatment intensification in patients with uncontrolled blood pressure (BP).

9  
10 **4 Design:** A retrospective cohort study in six public hospitals, Ethiopia

11  
12 **5 Participants:** Adult ambulatory hypertensive patients with at least one previously prescribed  
13  
14  
15 **6** antihypertensive medication in the study hospital.

16  
17 **7 Outcome:** Controlled BP (<140/90 mm Hg), and treatment intensification of patients with  
18  
19  
20 **8** uncontrolled BP.

21  
22 **9 Results:** The study population comprised of 897 patients. Their mean age was 57 (SD 14) years, 63%  
23  
24  
25 **10** were females, and 35% had one or more cardiometabolic comorbidities mainly diabetes mellitus. BP  
26  
27  
28 **11** was controlled in 37% patients. Treatment was intensified for 23% patients with uncontrolled BP. In  
29  
30  
31 **12** multivariable (logistic regression) analysis, determinants positively associated with controlled BP  
32  
33  
34 **13** were treatment at general hospitals (OR 1.89 [95% CI: 1.26; 2.83]) compared to specialized hospitals  
35  
36  
37 **14** and longer treatment duration (OR 1.04 [95% CI: 1.01; 1.06]). Negatively associated determinants  
38  
39  
40 **15** were previously uncontrolled BP (OR 0.30 [95% CI: 0.21; 0.43]), treatment regimens with diuretics  
41  
42  
43 **16** (OR 0.68 [95% CI, 0.50; 0.94]), and age (OR 0.99 [95% CI: 0.98; 1.00]). The only significant – positive –  
44  
45  
46 **17** determinant for treatment intensification was duration of therapy (OR 1.05 [95% CI: 1.02; 1.09]).

47  
48  
49 **18 Conclusions:** The level of controlled BP and treatment intensification practice in this study was low.  
50  
51  
52 **19** The findings suggest the need for in-depth understanding and interventions of the identified  
53  
54  
55 **20** determinants such as uncontrolled BP on consecutive visits, older age, and type of hospital.

56  
57  
58 **21 Key words:** hypertension, antihypertensive medication, blood pressure control, treatment  
59  
60  
**22** intensification, ambulatory patients, Ethiopia, hospital, observational study

1  
2  
3 **1 STRENGTH AND LIMITATIONS**  
4

- 5 2 • This is the first study that gives insight into determinants of hypertension treatment practice  
6  
7 3 (level of BP control and treatment intensification) in a diverse population treated in public  
8  
9 4 hospitals in Ethiopia.  
10  
11 5 • We analysed BP measurements as recorded in patient medical records, which reflect actual  
12  
13 6 clinical practice, but may be subject to recording and measurement error.  
14  
15 7 • The finding of this study may not be generalizable to other settings such as private practice or  
16  
17 8 primary health care centers in Ethiopia.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 BACKGROUND

2 Hypertension is a major risk factor for cardiovascular diseases, and it is the leading cause of death  
3 and disability globally.[1] The World Health Organization (WHO) recently reported that 80% of  
4 deaths due to cardiovascular disease occur in low- and middle-income countries, with the highest  
5 death rate reported in African countries. The report also indicated that prevalence of hypertension in  
6 adults was higher in Africa (46%) than for instance in the US (35%).[1] Hypertension is also more  
7 prevalent among people from Africa living in the Western world than among whites.[2] The  
8 population of African ancestry is characterized by high vascular contractility, extreme salt sensitivity,  
9 and low renin release.[3-5] Hence, over-activation of the sympathetic nervous system and renin-  
10 angiotensin-aldosterone system is more prevalent in this population, making them more vulnerable  
11 to high blood pressure. In addition, changes in environmental factors such as economic  
12 development, urbanization, and lifestyle have resulted in an epidemiological transition from  
13 infectious to non-communicable disease such as hypertension in the African region.[6]

14 Large clinical outcome studies have repeatedly shown that treating hypertension using evidence  
15 based antihypertensive treatment and/or adjusting lifestyle improves cardiovascular outcomes.[7]  
16 However, achieving target blood pressure (BP) level remains a challenge in clinical practice. The  
17 majority of studies in Africa have shown that less than a third of patients achieve treatment goals.[8]  
18 Generally, four main factors have been identified that influence achieving controlled BP. First, there  
19 are factors intrinsic to the nature of the disease; in most cases hypertension is initially asymptomatic  
20 and this delays early prevention, diagnosis, and treatment.[9] Second, poor treatment response may  
21 be due to patient-related factors such as age, gender, race, awareness, and compliance to  
22 medication.[4,10] Third, there are healthcare system-related factors such as lack of effective  
23 hypertension prevention and treatment programs, and access to medications. Fourth, prescriber  
24 behavior, competences, and large patient-to-prescriber ratio affect hypertension prevention and

1  
2  
3 1 treatment outcomes. The majority of these factors have been extensively studied in western  
4  
5 2 societies; however, little is known of their impact on BP control in developing nations. Some of these  
6  
7 3 factors may be unique to, or more pronounced in the African setting, including low societal  
8  
9 4 awareness, priority to fight infectious diseases, and human resource limitations, in particular the  
10  
11 5 number of available healthcare professionals.[6,11]  
12  
13

14  
15 6 Prevention and treatment strategies have been shown to be effective in optimizing BP control in  
16  
17 7 the western world.[12] Such programs may be relevant for the African setting. In order to guide  
18  
19 8 targeted interventions studies, identifying factors contributing to poor BP control in the African  
20  
21 9 setting are urgently needed. Studies on hypertension conducted to date in Ethiopia, the second most  
22  
23 10 populous country (approximately 100 million) in Africa, have focused on determining prevalence of  
24  
25 11 the disease.[13-15] Prevalence is relatively low (10 – 30%), [1,13-15], but further data on  
26  
27 12 hypertension treatment practices are lacking.[16,17] Therefore, we aimed to assess the proportion  
28  
29 13 of patients treated for hypertension who had controlled BP and identify determinants for achieving  
30  
31 14 BP control in an Ethiopian setting. Additionally, we aimed to study whether treatment was  
32  
33 15 intensified in those patients with uncontrolled BP and identify the determinants for treatment  
34  
35 16 intensification.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1     **METHODS**

### 2     **Study design and setting**

3     This retrospective cohort study was conducted in outpatient clinics of six public hospitals in Addis  
4     Ababa (capital city) and Tigray regional state, Ethiopia. We included two specialized hospitals (Addis  
5     Ababa), and four general hospitals, three from Tigray and one from Addis Ababa. Specialized  
6     (tertiary) hospitals are at the top tier of Ethiopian public healthcare system and serve approximately  
7     five million people. The general (secondary) hospitals are estimated to serve 1-1.5 million people.  
8     Furthermore, patients including those with hypertension are usually treated first at a primary  
9     healthcare center.[18]

### 10    **Study population**

11    Participants were approached while waiting for their appointment in the waiting area of  
12    hypertension outpatient clinics, where known hypertensive patients come for regular follow-up  
13    visits. Participants were recruited consecutively after giving consent. Hypertensive patients aged 18  
14    years or older were included, if they had at least one previous antihypertensive medication  
15    prescription in the same hospital, and gave informed consent. Patients were identified based on self-  
16    reported hypertension or based on a mark on their pocket-size appointment card as being  
17    hypertensive. We verified in each clinic log-book (if available) and from individual patient medical  
18    records if patients met the inclusion criteria as they had indicated during the interviews.

19    Routine practice in the study hospitals is that nurses measure the patient's blood pressure and  
20    assign the patient to a physician. The physician then performs a consultation, confirms the  
21    hypertension diagnosis, if necessary performs further examinations including rechecking BP, and  
22    renews or amends prescribed medication. Patients then collect their medicine from pharmacy  
23    outlets at the same hospital or from private or community pharmacies.



## 1 Data collection

2 Included patients were interviewed in the waiting area before they were seen by the physician. Data  
3 collected via interview included socio demographics, medication adherence, and duration of  
4 antihypertensive treatment with medication. The socio demographics variables were age, sex,  
5 educational and marital status, alcohol use, and smoking habits. Clinical information retrieved from  
6 medical records were BP measurements, medication prescriptions, and comorbid illnesses, and  
7 information was retrieved for the *current visit* and the previous (*prior visit*). Data were collected by  
8 professional nurses or pharmacists who were trained in using a dedicated case-report form. Data  
9 were collected between February and August 2015.

## 10 Variables

### 11 Outcome measures

12 We defined two *outcome measures*. First, for *BP control* we used the 'standard' definition of  
13 controlled BP, i.e., systolic BP/diastolic BP below 140/90 mm Hg at the current visit.[12] Second, we  
14 defined *treatment intensification* as an increase in dose of an antihypertensive drug and/or addition  
15 of one or more antihypertensive drug(s). Treatment intensification was calculated for those patients  
16 who had a complete medication history (including dose and administration frequency) at both  
17 current and prior visits and whose BP was not controlled at the current visit. A switch in drug class  
18 was not considered as treatment intensification.

### 19 Explanatory variables

20 For determinants of BP control or treatment intensification, we included socio demographic variables  
21 (age in year, gender, smoking history, alcohol use, marital status, and educational status), hospital  
22 type (general versus specialized), cardiometabolic comorbid illnesses (diabetes mellitus (DM),  
23 dyslipidemia, kidney disease, heart failure/myocardial infarction), uncontrolled BP ( $\geq 140/90$  mm Hg)  
24 at the prior visit, duration of antihypertensive treatment in years, treatment adherence with the

1  
2  
3 1 eight-point Morisky Medication adherence scale, MMAS-8 ( $\geq 7$ : yes/no), visit schedule in month, and  
4  
5 2 antihypertensive medications prescribed at the prior visit. For alcohol use and smoking habit,  
6  
7 3 participants were asked if they were active smokers or consume alcohol up to our survey date, i.e.  
8  
9 4 smoking history (Yes: current smokers, and No: never smoke or ex-smoker), alcohol use (Yes:  
10  
11 5 regularly or sometimes, and No: never consume alcohol). The visit schedule was calculated by taking  
12  
13 6 the difference in days between the current and prior visits divided by 30, i.e., indicating the length of  
14  
15 7 time (duration) between the two follow-up visit expressed in months.  
16  
17  
18

19 8 Antihypertensive medication adherence was measured with the eight-point Morisky Medication  
20  
21 9 adherence scale (MMAS-8), which has been previously validated for hypertensive patients.[19,20]  
22  
23 10 The items of the scale are grouped into three aspects. The first aspect is about sometimes forgetting  
24  
25 11 or intentionally not taking prescribed medication (item 1), and more specifically in the past two  
26  
27 12 weeks (item 2), or under special circumstances during travel/leaving home (item 4), and finally asking  
28  
29 13 if medication was taken yesterday (item 5). The second aspect is about intentionally stopping or  
30  
31 14 cutting back medication because of feeling worse (item 3) or because of a feeling that BP is under  
32  
33 15 control (item 6). The last aspect relates to convenience (item 7) or inconvenience frequency of  
34  
35 16 difficult times to take medication (item 8). The scale was translated into two Ethiopian languages  
36  
37 17 (Amharic and Tigrigna) according to the method described by Beaton *et al.*[21] A total score of seven  
38  
39 18 or more (maximum eight) was considered to be adherent to antihypertensive medication; i.e., MMAS  
40  
41 19  $\geq 7$ . [19] For a sensitivity analyses, we used a lower level of adherence with a cut-off of MMAS  $\geq 6$ .  
42  
43  
44  
45  
46  
47

#### 48 **Sample size**

49  
50 21 Achieved sample size was based on an estimated 30% prevalence of controlled BP among treated  
51  
52 22 hypertensive patients in Ethiopia [8,15] and a single proportion sample size calculation formula. The  
53  
54 23 total sample size was 984 (164 per hospital) with 0.80 power, 95% confidence interval, 3% margin of  
55  
56 24 error, and an estimated 10% none response rate, or incomplete/irretrievable patient records.  
57  
58  
59  
60

## 1 **Statistical analyses**

2  
3  
4  
5 2 Descriptive statistics were used to summarize socio demographic, disease characteristics of the study  
6  
7  
8 3 population, and nature and frequency of antihypertensive medications used. Multivariable logistic  
9  
10 4 regression analyses were applied to investigate determinants for achieving target BP at current visit  
11  
12 5 and determinants for treatment intensification. Statistical significance was considered at p value <  
13  
14 6 0.05. Potential determinants with p < 0.2 in bivariable analyses were included into the multivariable  
15  
16  
17 7 logistic model. Microsoft access 10 and SPSS version 22.0 statistical software was used for data entry  
18  
19 8 and analyses, respectively.

## 9 **Sensitivity analyses**

10 We performed five sensitivity analyses. First, tighter BP targets at the current visit (BP <130/80 mm  
11 Hg) were applied for those patients with diabetes mellitus (DM) and/or renal disease. Standard BP  
12 target (BP < 140/90 mm Hg) was used for all others participants. Second, we performed a sensitivity  
13 analysis for the main outcome measure (controlled BP < 140/90) using a different cut off for  
14 adherence (MMAS  $\geq$  6). Third (for controlled BP) and fourth (for treatment intensification) sensitivity  
15 analysis were similar to the main analysis with three modified determinants. Graded hypertension  
16 (prior BP) was performed according to the stages defined by the Ethiopian standard treatment  
17 guideline for hypertension: normal BP (systolic BP < 120 and DBP < 80 mm Hg), pre-hypertensive  
18 stage (systolic BP 120-139 or diastolic BP 80-89 mm Hg), stage-I hypertension (systolic BP 140-159 or  
19 diastolic BP 90-99 mm Hg), and stage-II hypertension (systolic BP  $\geq$  160 or diastolic BP  $\geq$  100 mm  
20 Hg).[22] These analysis also included the number of cardiometabolic comorbid illnesses as a proxy  
21 measure for more severely ill patients and age categorized in to five groups. Patients with higher  
22 hypertension stages and multiple comorbid illness were hypothesized to be more difficult to treat. A  
23 fifth sensitivity analysis was performed in patients who had been on medication for at least six  
24 months, assuming that these patients were no longer in the initial careful up-titration phase.

1  
2  
3 **1 Ethics approval**  
4

5 2 This study was approved by Ethiopian Health Research Ethical Review Committees of (i) the College  
6  
7 3 of Health Sciences, Mekelle University, (ii) St Paul's Hospital Millennium Medical College, and (iii) the  
8  
9 4 Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa  
10  
11 5 University. All individual participants included in this study consented to participation.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## 1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28           29           30           31           32           33           34           35           36           37           38           39           40           41           42           43           44           45           46           47           48           49           50           51           52           53           54           55           56           57           58           59           60

1           2           3           4           5           6           7           8           9           10           11           12           13           14           15           16           17           18           19           20           21           22           23           24           25           26           27           28           29           30           31           32           33           34           35           36           37           38           39           40           41           42           43           44           45           46           47           48           49           50           51           52           53           54           55           56           57           58           59           60

**RESULTS**

We were able to approach 968 patients at six public hospitals in Ethiopia. Seventy-one patients were excluded from our analyses: eight refused to participate, six were not hypertensive, and 57 patients had no retrievable records or incomplete records (missing BP at current visit). This resulted in a study population of 897 patients (Figure 1). The majority of included patients (93%) reported to have come for their regular hypertension follow-up visit. The remaining 7% had (perceived) symptoms, uncontrolled hypertension, or adverse events. The mean (SD) patient age was 57 (14) years, 63% of patients were female, most patients (65%) were married, and 64% had no formal education or only attended primary school. Almost all (94%) had never smoked, and nearly half (43%) consumed alcohol regularly or occasionally (Table 1). At the current visit, 35% study participants had at least one recorded comorbid illness, predominantly DM (Table 1).

**Table 1 Characteristics of ambulatory hypertensive patients at two visits, Ethiopia**

Characteristics	Current visit	Prior visit
<b>Demographics</b>		
Age (mean, SD), Year	57 (14)	
Female (n, %)	551 (63)	
Smoking [current smoker] (n, %)	57 (6)	
Alcohol use [regularly or sometimes] (n, %)	378 (43)	
Married (n, %)	567 (65)	
Education (n, %)		
University/college education	170 (20)	
Secondary education	141 (16)	
Primary or no formal education	557 (64)	
<b>Setting</b>		
Specialized hospitals: both from Addis Ababa (n, %)		
Tikur Anbessa Hospital	139 (16)	
St. Paul's Hospital	153 (17)	
General hospitals: all from Tigray, except Yekatit 12 from Addis Ababa (n, %)		
St. Mary Axum Hospital	139 (16)	
Mekelle Hospital	152 (17)	
Lemlem Karl Maychew Hospital	155 (17)	
Yekatit 12 Hospital	159 (18)	
<b>Disease characteristics</b>		
Blood pressure (BP)		
Systolic BP (Mean, SD)	139 (21)	144 (22)
Diastolic BP (Mean, SD)	84 (11)	85 (13)
Controlled BP (<140/90 mm Hg) (n, %)	335 (37)	231 (27)
Controlled BP (<130/80 mm Hg with DM &/or kidney diseases, #otherwise <140/90 mm Hg) (n, %)	268 (30)	202 (24)
Cardiometabolic comorbid illnesses (n, %)		
Diabetes Mellitus	227 (25)	198 (22)
Dyslipidemia	57 (6)	45 (5)
Renal diseases	25 (3)	23 (3)
Heart failure / myocardial infarction	72 (8)	60 (7)
<b>Antihypertensive treatment characteristics</b>		
Drug class (n, %)		
ACE inhibitors	503 (56)	494 (55)
Enalapril	499 (56)	492 (55)
Lisinopril or captopril	4 (0.4)	2 (0.2)
Beta blockers	167 (19)	166 (19)
Atenolol	148 (17)	147 (16)
Propranolol, metoprolol or carvedilol	19 (2)	19 (2)
Calcium channel blockers	449 (50)	439 (49)
Nifedipine	381 (43)	389 (43)
Amlodipine or felodipine	68 (8)	50 (6)
Diuretics †	498 (56)	486 (54)
Hydrochlorothiazide	428 (48)	421 (47)
Furosemide	76 (9)	71 (8)
Spironolactone	72 (8)	66 (7)
Others (methyldopa, nitrates or losartan)	19 (2)	13 (1)
Duration of therapy years (Median, interquartile rang)	4 (7)	
Visit schedule in months (mean, SD)	2.3 (2.0)	
Adherence (MMAS ≥ 7) (n, %)	355 (40)	
Therapy (n, %)		
Monotherapy	343 (38)	363 (41)
Multidrug therapy	550 (62)	521 (59)
Treatment intensified in patients with uncontrolled BP at current visit (n=540) * (n, %)	123 (23)	

2 Mono/Multidrug therapy is limited to antihypertensive medications. \*For 22 of 562 patients with uncontrolled BP at the current  
3 visit the medication history was not complete. Treatment intensification could thus only be calculated for 540 patients. † Some  
4 patients had more than one type of diuretics. #otherwise: hypertensive patients without DM or kidney disease.

1  
2  
3 1 Thirty-seven percent (n = 335) of the participants had controlled BP at the current visit (Table 1).  
4  
5 2 Applying the stricter BP target for patients with DM and/or renal disease (BP<130/80 mm Hg), the  
6  
7 3 proportion of patients with controlled BP dropped to 27% (n = 231).  
8  
9

10 4 Only 23% of 540 patients with uncontrolled BP and complete medication history had their  
11  
12 5 treatment intensified (Table 1). For 22 (4%) of 562 patients with uncontrolled BP at the current visit,  
13  
14 6 the medication history was not complete. Either the dose and/or administration frequency were  
15  
16 7 missing. The antihypertensive medication adherence rate (MMAS  $\geq$  7) was 40%, (Table 1), and 57%  
17  
18 8 for the lower cut off, MMAS  $\geq$  6 (Supplement Table 1).  
19  
20

21 9 Overall, angiotensin-converting-enzyme (ACE) inhibitors were the most commonly prescribed  
22  
23 10 group of drugs (n = 503), followed by diuretics (n = 498) (Table 1). Medication use was quite similar  
24  
25 11 on both visits. At the current visit 62% of included patients were prescribed a multidrug treatment  
26  
27 12 regimen and 45% patients took two antihypertensive agents (Supplement Table 2). Most (38 %) of  
28  
29 13 the 343 patients on monotherapy were prescribed diuretics (n = 127).  
30  
31  
32

#### 33 14 **Determinants of BP Control**

##### 34 15 *BP <140/90 mm Hg (primary analysis)*

35  
36 16 According to our multivariable logistic regression model (Table 2), factors significantly associated  
37  
38 17 with achieving target BP at the current visit were age (OR 0.99 [95% CI: 0.98; 1.00]), follow-up at  
39  
40 18 general hospitals (OR 1.89 [95% CI: 1.26; 2.83]), inadequately controlled BP at prior visit (OR 0.30  
41  
42 19 [95% CI: 0.21; 0.43]), longer treatment duration per year (OR 1.04 [95% CI: 1.01; 1.06]), and  
43  
44 20 prescribed diuretics (OR 0.68 [95% CI: 0.50; 0.94]).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Table 2 Determinants of achieving target BP (BP < 140/90) at current visit in ambulatory hypertension patients**

Variables	Controlled BP		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), year	58 (13)	56 (15)	#0.99 [0.98; 1.00]	<b>*0.988 [0.976; 0.997]</b>	
Gender (n, %)	Male	219 (67)	109 (33)	Ref	
	Female	331 (60)	220 (40)	*1.34 [1.00; 1.78]	1.12 [0.80; 1.55]
Smoking (n, %)	No	514 (62)	312 (38)	Ref	
	Yes	37 (65)	20 (35)	0.89 [0.51; 1.56]	
Alcohol use (n, %)	No	310 (63)	184 (37)	Ref	
	Yes	232 (61)	146 (39)	1.06 [0.81; 1.40]	
Marital status (n, %)	Single	187 (60)	124 (40)	Ref	
	Married	359 (63)	208 (37)	0.87 [0.66; 1.16]	
Educational status (n, %)	College/University	110 (65)	60 (35)	Ref	
	Secondary	86 (61)	55 (39)	1.17 [0.74; 1.86]	
	Primary /not formal	345 (62)	212 (38)	1.13 [0.79; 1.61]	
Hospital type (n, %)	Specialized	199 (68)	93 (32)	Ref	
	General	363 (60)	242 (40)	*1.43 [1.06; 1.92]	<b>*1.89 [1.26; 2.83]</b>
<b>Disease characteristics (n, %)</b>					
Diabetes Mellitus	No	413 (62)	257 (38)	Ref	
	Yes	149 (66)	78 (34)	0.84 [0.61; 1.15]	
Dyslipidemia	No	523 (62)	317 (38)	Ref	
	Yes	39 (68)	18 (32)	0.76 [0.43; 1.35]	
Renal disease	No	542 (62)	330 (38)	Reference	
	Yes	20 (80)	5 (20)	#0.41 [0.15; 1.10]	0.58 [0.19; 1.71]
Heart failure/ MI	No	518 (63)	307 (37)	Ref	
	Yes	44 (61)	28 (39)	1.07 [0.66; 1.76]	
Controlled BP at prior visit	No	424 (68)	199 (32)	*0.37 [0.27; 0.51]	<b>*0.30 [0.21; 0.43]</b>
	Yes	102 (44)	129 (56)	Ref	
<b>Antihypertensive Treatment characteristics</b>					
Duration of therapy, years (mean, SD)	6.2 (6.4)	7.4 (8.3)	#1.02 [1.00; 1.04]	<b>*1.04 [1.01; 1.06]</b>	
Adherent (MMAS $\geq 7$ ) (n, %)	No	319 (60)	212 (40)	Ref	
	Yes	233 (66)	122 (34)	#0.79 [0.60; 1.04]	0.80 [0.58; 1.09]
Revisit schedule in months (Mean, SD)	2.2 (1.4)	2.0 (1.2)	*0.89 [0.82; 0.97]	0.91 [0.82; 1.02]	
Therapy at prior visit (n, %)	Monotherapy	225 (62)	138 (38)	Ref	
	Multidrug	326 (63)	195 (37)	0.98 [0.74; 1.29]	
<b>Antihypertensive medications at prior visit</b>					
ACE inhibitors (n, %)	No	259 (64)	144 (36)	Ref	
	Yes	303 (61)	191 (39)	1.13 [0.86; 1.49]	
Beta blockers (n, %)	No	472 (65)	259 (35)	Ref	
	Yes	90 (54)	76 (46)	*1.54 [1.09; 2.16]	1.42 [0.95; 2.10]
Calcium channel blockers (n, %)	No	290 (63)	168 (37)	Ref	
	Yes	272 (62)	167 (38)	1.06 [0.81; 1.39]	
Diuretics (n, %)	No	243 (59)	168 (41)	Reference	
	Yes	319 (66)	167 (34)	*0.76 [0.58; 0.99]	<b>*0.68 [0.50; 0.94]</b>

2 Only patients with available data were included in the analyses, therefore numbers may sometimes differ from Table 1. Percentages are calculated per  
3 a row. Statistically significant values: \*p < 0.05 at 95% CI. Variables with #p < 0.20 or \*p < 0.05 in the bivariable model were included in the multivariable  
4 model. Mono/Multidrug therapy was for antihypertensive medications.



## 1 **Determinant of treatment intensification**

2  
3  
4  
5  
6 The only statistically significant determinant for treatment intensification in the multivariable  
7  
8  
9 analyses was longer treatment duration (OR 1.05 [95% CI: 1.02; 1.09]) (Table 3).

### 10 *Sensitivity (secondary) analysis*

11  
12  
13  
14 In our first sensitivity analyses, using BP <130/80 mm Hg for patients with DM and/or renal disease,  
15  
16  
17 and for all other patients <140/90 mm Hg as cut-offs, uncontrolled BP at the prior visit had a negative  
18  
19  
20 effect on achieving target BP at the current visit (OR 0.25 [95% CI: 0.17; 0.37]). Medications  
21  
22  
23 prescribed during the prior visit, except diuretics (OR 0.60 [95% CI: 0.40; 0.90]), were not significantly  
24  
25  
26 associated with achieving controlled BP at the current visit. Unlike the primary analyses, age,  
27  
28  
29 treatment duration, and hospital type did not show statistically significant effects on current visit BP  
30  
31  
32 status (Supplement Table 3).

33  
34  
35 In the sensitivity analyses for BP control (Supplement Table 4) and treatment intensification  
36  
37  
38 (Supplement Table 5), the results were mostly similar with the main analysis (Table 2 and 3,  
39  
40  
41 respectively). As expected, more severe hypertension stage was associated with more difficulty to  
42  
43  
44 achieve target BP: stage-II hypertension (OR 0.17 [95% CI 0.09;0.35]), and stage-I hypertension (OR  
45  
46  
47 0.34 [95% CI 0.17;0.67]). However, the number of comorbid illness was not a significant determinant  
48  
49  
50 of achieving target BP. In case of age, older age groups were less likely to achieve target BP than  
51  
52  
53 younger age groups (< 35 years): 55-64 years old (OR 0.41 [95% CI 0.20; 0.83]) and ≥ 65 years old (OR  
54  
55  
56 0.46 [95 CI: 0.22;0.93]). Supplementary analysis for treatment intensification (Supplement Table 5)  
57  
58  
59 gave similar results with main analysis on Table 3, where only duration of therapy was a significant  
60  
determinant (OR 1.05 [95% CI: 1.02; 1.08]) for more treatment intensification. The majority (94%) of  
participants had been on medication for at least for six months. Exclusion of the 6% of patients who  
had recently started therapy (< 6 months ago) in the sensitivity analysis (Supplement Table 6) did not

- 1  
2  
3 1 change our findings reported in Table 2. The proportion of patients with controlled BP 303 (39%)  
4  
5 2 remained similar as well. Duration of therapy remained a significant determinant for achieving target  
6  
7 3 BP and for intensifying treatment.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 **Table 3 Treatment intensification determinants for ambulatory hypertension patients with uncontrolled BP at current visit**

Variables	Treatment intensified		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), Year	57 (13)	60 (13)	#1.02 [1.00; 1.03]	1.02 [1.00; 1.04]	
Gender (n, %)	Male	167 (80)	41 (20)	Ref	
	Female	241 (75)	80 (25)	#1.35 [0.88; 2.07]	1.47 [0.91; 2.37]
Smoking (n, %)	No	383 (77)	113 (23)	Ref	
	Yes	27 (79)	7 (21)	0.88 [0.37; 2.07]	
Alcohol use (n, %)	No	225 (76)	73 (25)	Ref	
	Yes	180 (80)	44 (20)	0.75 [0.49; 1.15]	
Marital status (n, %)	Single	138 (77)	42 (23)	Ref	
	Married	269 (78)	76 (22)	0.93 [0.60; 1.43]	
Educational status (n, %)	College/University	82 (78)	23 (22)	Ref	
	Secondary	58 (70)	25 (30)	1.54 [0.80; 2.97]	
	Primary/not formal education	262 (79)	70 (21)	0.95 [0.56; 1.62]	
Hospital type (n, %)	Specialized	137 (73)	51 (27)	Ref	
	General	280 (80)	72 (21)	#0.69 [0.46; 1.04]	0.83 [0.51; 1.37]
<b>Disease characteristics (n, %)</b>					
Diabetes Mellitus at current visit	No	311 (79)	84 (21)	Ref	
	Yes	106 (73)	39 (27)	#1.36 [0.88; 2.11]	1.10 [0.67; 1.81]
Dyslipidemia at current visit	No	388 (77)	113 (23)	Reference	
	Yes	29 (74)	10 (26)	1.19 [0.56; 2.50]	
Renal disease at current visit	No	403 (77)	118 (23)	Ref	
	Yes	14 (74)	5 (26)	1.22 [0.43; 3.45]	
Heart Failure / MI at current visit	No	384 (77)	112 (23)	Ref	
	Yes	33 (75)	11 (25)	1.14 [0.56; 2.33]	
Controlled BP at prior visit	No	312 (77)	96 (24)	#1.50 [0.85; 2.66]	1.38 [0.76; 2.50]
	Yes	83 (83)	17 (17)	Ref	
<b>Antihypertensive treatment characteristics</b>					
Duration of therapy yrs (mean SD)	5.7 (4.1)	8.1 (7.4)	*1.05 [1.02; 1.08]	*1.05 [1.02; 1.09]	
Adherence (MMAS $\geq$ 7) (n, %)	No	232 (76)	73 (24)	Ref	
	Yes	178 (78)	49 (22)	0.88 [0.58; 1.32]	
Therapy at prior visit (n, %)	Monotherapy	168 (76)	53 (24)	Ref	
	Multidrug therapy	249 (78)	70 (22)	0.89 [0.59; 1.34]	

2 Statistically significant values: \*p < 0.05 at 95% CI. Variable with #p < 0.2 or \*p < 0.05 in the bivariable model were included in the multivariable model.  
3 Percentages are calculated per row. Treatment intensification was calculated for 540 patients who had complete medication history (including dose and  
4 frequency) on both visits and uncontrolled BP at current visit.

## 1 DISCUSSION

2 In this study, nearly two-thirds of patients on antihypertensive medication had uncontrolled BP.  
3 Drugs were prescribed from four antihypertensive drug classes, ACE-inhibitors, diuretics, calcium  
4 channel blockers, and beta blockers. Generally, a single specific agent (over 90%) was prescribed  
5 within a class, enalapril, hydrochlorothiazide, nifedipine, and atenolol, respectively. Age of patients,  
6 uncontrolled BP at the prior visit, and a treatment regimen containing diuretics contributed to  
7 poorer BP control. Follow-up in a general hospital compared to a specialized hospital and longer  
8 treatment duration were associated with a better BP control. Duration of therapy on  
9 antihypertensive medication was the only, albeit modestly, significant contributing factor of  
10 treatment intensification (also for achieving target BP).

11 When looking at other studies on hypertension awareness, treatment and control in Africa, 41 out  
12 of 44 studies showed a lower proportion of patients with controlled BP (these studies reported levels  
13 of control ranging from <1% to 33%) than our study.[8] The reported wide variation could be  
14 explained by population differences and variation in study set-ups. The level of BP control in our  
15 study was between that reported in two studies performed in a Southern Ethiopian hospital.[16,23]  
16 Gudina *et al.* studied the prevalence of hypertension among patients visiting a hospital for any  
17 reason, and of patients with known hypertension, 44% were controlled.[23] In the other study, 50%  
18 of patients had achieved their target BP.[16]. This study was more of similar to ours; patients were  
19 included who visited an outpatient hypertension clinic and who had been treated for at least 12  
20 months in the study hospital.[16] Unfortunately, information on duration of the therapy was not  
21 included in these studies.[16,23] In comparison with studies from western countries, the percentages  
22 of patients with adequately controlled BP and those who received treatment intensification were  
23 lower in our study than in North American countries, but similar to some European countries.[24,25]  
24 These differences may be explained in part by different national guidelines recommendations.

1  
2  
3 1 However, as reported elsewhere, it is not only differences between guidelines, but also how much  
4  
5 2 effort countries put in implementation of these recommendations.[25] While the Ethiopian guideline  
6  
7 3 is similar to the USA guidelines,[22,24] possible differences in implementation, due to African factors  
8  
9 4 including resource limitations, low priority for non-communicable diseases, and healthcare providers'  
10  
11 5 behavior and skills may in part explain the low level of BP control.[26] However, comparing our  
12  
13 6 results with population-based studies in western countries or those in other parts of Africa should be  
14  
15 7 done with caution as we investigated two regional Ethiopian hypertensive populations treated at a  
16  
17 8 hospital setting only.

21  
22 9 In our study, one of the determinants for achieving target BP was the healthcare setting. Patients  
23  
24 10 who are referred to specialized hospitals may be more complex – in terms of comorbidities or  
25  
26 11 severity of hypertension. Numerically, patients received more treatment intensification at specialized  
27  
28 12 hospitals (27%) than at generalized hospitals (21%), although these differences were not significant  
29  
30 13 in our bi-and multivariable analyses (Table 3). Thus, the additional effort provided in these  
31  
32 14 specialized hospitals may have not been sufficient to offset the difficulties in achieving BP control in  
33  
34 15 the more complex patient population. Younger age was another significant determinant for achieving  
35  
36 16 target BP. Prescribers in our study may have accepted higher BP in older patients, possibly because  
37  
38 17 of tolerability or perceived lack of need for tight BP control. Recent evidence, however, suggests that  
39  
40 18 “the lower is the better”, also in older patients.[27,28] Nevertheless, guidelines lack consistency on  
41  
42 19 BP targets for the elderly,[29] especially when patients are frail and doctors may not aim for tight BP  
43  
44 20 control. Another determinant of BP control was the type of medication prescribed. Most of our study  
45  
46 21 participants received diuretics, the first line antihypertensive agents. We have no data in which order  
47  
48 22 medication was initiated. Therefore, we can only speculate why treatment regimens containing these  
49  
50 23 drugs did not show better BP control. Since three-quarters of diuretics-containing regimens in our  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 study existed of two drugs only (Supplement Table 2), patients may need additional antihypertensive  
4  
5 2 therapy.

6  
7 3 Only one fifth of patients with uncontrolled BP at the current visit had their treatment intensified.  
8  
9 4 Longer treatment duration was the only statistically significant determinant for intensification.  
10  
11 5 Possibly, it took some while before prescribers could intensify treatment. Ultimately, the lack of BP  
12  
13 6 control at the prior visit was the strongest predictor of patients not having controlled BP at current  
14  
15 7 visit. This seems to suggest some level of 'clinical inertia', where doctors are slow to respond to  
16  
17 8 clinical parameters. This practice indicates a need to intensify therapy. Indeed, a lack of achieving BP  
18  
19 9 control may also be explained by true therapy resistant hypertension (although only 17% of patients  
20  
21 10 received three or more antihypertensive agents at the prior visit).[30-33] Moreover, prescribers may  
22  
23 11 not intensify treatment if they suspect that increased BP levels may be related to a suspected or  
24  
25 12 reported poor compliance for a particular patient. (Poor) medication adherence is known as an  
26  
27 13 important determinant for controlling hypertension.[34] The level of adherence we observed (40%  
28  
29 14 and 57% for MMAS-8 with a cut-off at  $> 6$  and  $\geq 6$  respectively) was close to that reported by  
30  
31 15 Asgedom *et al.* (35% and 61% respectively).[16] Two other Ethiopian studies reported low levels of  
32  
33 16 adherence, although more difficult to compare as they used a 4-point MMAS.[35, 36] Surprisingly,  
34  
35 17 the level of adherence was not associated with BP control in our main and sensitivity analyses  
36  
37 18 (Supplement Table 1). Similarly in the study by Asgedom *et al.*, a hospital-based study in Southern  
38  
39 19 Ethiopia, no relation with adherence and BP control was observed.[16] Self-reported medication  
40  
41 20 adherence may be overestimated and therefore lead to bias.

42  
43 21 We found that more hypertensive women than men were included in our study, and that few  
44  
45 22 patients smoked. Our study was not a population study designed to evaluate prevalence of  
46  
47 23 hypertension, and the reason why more women were included could have been that women seek  
48  
49 24 more care than men. Although a recent community-based study evaluating prevalence of  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 hypertension in Ethiopia suggested more women were hypertensive than men,[13] a meta-analysis  
4  
5 2 including hospital-based studies [15] and another recent hospital-based study reported a higher  
6  
7 3 prevalence of males with hypertension.[16] The higher prevalence of women in our study does not  
8  
9 4 appear to have a strong impact on our study findings, as gender was not a significant determinant for  
10  
11 5 BP control BP or treatment intensification.

12  
13  
14 6 Poor hypertension control should be addressed in a holistic approach that includes lifestyle  
15  
16 7 modification and management of comorbid illnesses. Our study was largely performed in urban areas  
17  
18 8 with the highest prevalence of hypertension in Ethiopia, likely attributed to adoption of a Western  
19  
20 9 lifestyle.[15] Still, our patient population looks very different from that in European or USA studies,  
21  
22 10 i.e., few smokers and few patients with (known) cardiometabolic comorbidities.

### 23 24 25 26 11 **Strengths and limitations**

27  
28  
29 12 As far as we are aware, this was the first study of its kind in Ethiopia covering a relatively diverse  
30  
31 13 population. Our data included patients from hypertension outpatient clinics of six public hospitals in  
32  
33 14 the capital city and northern region of Ethiopia.

34  
35  
36 15 A limitation of our study was the validity of the BP measure used. We analysed BP measurements  
37  
38 16 as recorded in patients' medical records that reflected actual clinical practice, but these values may  
39  
40 17 be subject to recording and measurement error. It is not clear how prescribers considered  
41  
42 18 measurement variability or if any attempt was made to avoid "white-coat" hypertension, e.g., by  
43  
44 19 repeating BP measurement. Still, many observational studies use medical records – with data  
45  
46 20 collected in routine practice – as a data source. Future studies may consider using standardized  
47  
48 21 assessment of BP. In our study, the level of BP control was assessed for two consecutive visits only.  
49  
50 22 Follow-up at more visits may still be needed, as achieving BP control may require more time, and  
51  
52 23 would thus provide a better understanding of doctors truly being slow to intensify treatment.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 Another limitation is that medical records did not include extensive or well-structured patient  
4  
5 2 information. For example, comorbidities may be underreported. For this reason, we limited  
6  
7 3 evaluated comorbidities to cardiometabolic diseases as these are relevant to hypertension prognosis  
8  
9 4 and treatment and are more likely to have been recorded in the charts. We did not study if  
10  
11 5 prescribing was in line with guideline recommendations, e.g., based on comorbidities, but focused  
12  
13 6 instead on the actual impact of prescribing on BP. This study focused on public secondary and  
14  
15 7 specialized hospitals; therefore, the results may not be generalizable to other settings such as private  
16  
17 8 practices and primary health care centers. Differences in socio economic status did not seem related  
18  
19 9 with type of drug prescribed. This may have affected redeeming prescriptions at the pharmacy, but  
20  
21 10 we did not have that information. We did not query patients for economic reasons of non-  
22  
23 11 compliance, e.g. if they could afford their medication or that they needed to travel too far to collect  
24  
25 12 medication. We used the validated MMAS-8 questionnaire and did not want to overburden patients  
26  
27 13 further. Nevertheless, educational status – a proxy for socio economic status – in our study  
28  
29 14 population was not related to BP control.  
30  
31  
32  
33  
34

35  
36 15 Finally, as in all studies we were not able to include all previously reported potential confounders  
37  
38 16 for achieving BP control [35]. For example, type of prescriber (was difficult to retrieve from  
39  
40 17 medication charts), or medication counseling and patient's own knowledge of hypertension and  
41  
42 18 treatment goals (would have required further interview time) may require further study.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **1 CONCLUSION**

4  
5 2 Nearly two-thirds of patients on antihypertensive medication did not achieve target BP during  
6  
7 3 routine clinical follow-up, and only a quarter of these patients with uncontrolled BP received  
8  
9 4 treatment intensification. To improve care for patients visiting Ethiopian hospital hypertension  
10  
11 5 clinics, focus should be on older patients, and interventions may be needed for specialized centers.  
12  
13

14 **6 Acknowledgments**

15  
16  
17 7 Authors wish to thank study participants, data collectors, and study hospital administrators who  
18  
19 8 contributed to this study. The authors thank Michelle Pena for her valuable comments to the paper.  
20  
21

22 **9 Contribution**

23  
24 10 D.F. Berhe, K. Taxis and P.GM Mol designed and performed the research, analyzed, and interpreted  
25  
26 11 the data. F.M. Haaijer-Ruskamp, A. Mulugeta, and Y.T. Mengistu designed the study. All authors  
27  
28 12 participated in writing the manuscript, also read and approved the final version.  
29  
30

31 **13 Conflict of Interest:** There are no competing interests to declare.  
32

33 **14 Funding**

34  
35  
36 15 The study was part of a PhD project to the first author funded by Netherlands Organization for  
37  
38 16 International Cooperation in Higher Education (NUFFIC).  
39

40 **17 Data sharing statement**

41  
42  
43 18 No additional data are available for this specific study.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 REFERENCES**


- 4  
5 2 (1) World Health Organization. A global brief on hypertension: Silent killer, global public health crisis.  
6 3 2013. Available from  
7 4 [http://apps.who.int/iris/bitstream/10665/79059/1/WHO\\_DCO\\_WHD\\_2013.2\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf) [accessed on  
8 5 2016-05-17]
- 9  
10  
11 6 (2) Fuchs FD. Why do black Americans have higher prevalence of hypertension? an enigma still  
12 7 unsolved. *Hypertension* 2011;57:379-80.
- 13  
14 8 (3) Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to  
15 9 calcium blockers and diuretics than to ACE inhibitors and  $\beta$ -adrenergic blockers? A systematic review.  
16 10 *BMC med* 2013;11:1.
- 17  
18  
19 11 (4) Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. *Circulation* 2005;112:3562-  
20 12 3568.
- 21  
22  
23 13 (5) Sagnella G. Why is plasma renin activity lower in populations of African origin? *J Hum Hypertens*  
24 14 2001;15:17-25.
- 25  
26 15 (6) Dennison CR, Peer N, Steyn K, *et al.* Determinants of hypertension care and control among peri-  
27 16 urban Black South Africans: The HiHi study. *Ethn Dis* 2007;17:484-91.
- 28  
29  
30 17 (7) James PA, Oparil S, Carter BL, *et al.* 2014 evidence-based guideline for the management of high  
31 18 blood pressure in adults: report from the panel members appointed to the Eighth Joint National  
32 19 Committee (JNC 8). *JAMA* 2014;311:507-20.
- 33  
34 20 (8) Kayima J, Wanyenze RK, Katamba A, *et al.* Hypertension awareness, treatment and control in  
35 21 Africa: a systematic review. *BMC Cardiovasc Disord* 2013;13:54.
- 36  
37  
38 22 (9) Kessler CS, Joudeh Y. Evaluation and treatment of severe asymptomatic hypertension. *Am Fam*  
39 23 *Physician* 2010;81:470-6.
- 40  
41 24 (10) van de Vijver S, Akinyi H, Oti S, *et al.* Status report on hypertension in Africa-consultative review  
42 25 for the 6th Session of the African Union Conference of Ministers of Health on NCD's. *Pan Afr Med J*  
43 26 2013;16:38.
- 44  
45  
46 27 (11) Naicker S, Plange-Rhule J, Tutt RC, *et al.* Shortage of healthcare workers in developing countries-  
47 28 -Africa. *Ethn Dis* 2009;19 Suppl 1:S160-4.
- 48  
49  
50 29 (12) Mancia G, Fagard R, Narkiewicz K, *et al.* 2013 ESH/ESC guidelines for the management of arterial  
51 30 hypertension: The Task Force for the Management of Arterial Hypertension of the European Society  
52 31 of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Blood Press* 2013;22:193-278.
- 53  
54  
55 32 (13) Abebe SM, Berhane Y, Worku A, *et al.* Prevalence and associated factors of hypertension: a cross  
56 33 sectional community based study in Northwest Ethiopia. *PLoS One* 2015;10:e0125210.

- 1  
2  
3 1 (14) Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa:  
4 2 a systematic analysis. *PLoS One* 2014;9:e104300.  
5  
6 3 (15) Kibret KT, Mesfin YM. Prevalence of hypertension in Ethiopia: a systematic meta-analysis. *Public*  
7 4 *Health Reviews* 2015;36:14.  
8  
9  
10 5 (16) Asgedom SW, Gudina EK, Desse TA. Assessment of Blood Pressure Control among Hypertensive  
11 6 Patients in Southwest Ethiopia. *PLoS One* 2016;11:e0166432.  
12  
13 7 (17) Shukrala F, Gabriel T. Assessment of prescribing, dispensing, and patient use pattern of  
14 8 antihypertensive drugs for patients attending outpatient department of Hiwot Fana Specialized  
15 9 University Hospital, Harar, Eastern Ethiopia. *Drug Des Devel Ther* 2015; 9:519-23.  
16  
17  
18 10 (18) Federal Democratic Republic of Ethiopia Ministry of Health. Health sector transformation plan  
19 11 (HSTP)-2015/16 – 2019/20. Ethiopia Ministry of Health, 2015, p142. Available from  
20 12 [http://www.moh.gov.et/documents/26765/0/Health+Sector+Transformation+Plan/5542a23a-9bc7-](http://www.moh.gov.et/documents/26765/0/Health+Sector+Transformation+Plan/5542a23a-9bc7-46a2-8c1f-8b32c2603208?version=1.0)  
21 13 [46a2-8c1f-8b32c2603208?version=1.0](http://www.moh.gov.et/documents/26765/0/Health+Sector+Transformation+Plan/5542a23a-9bc7-46a2-8c1f-8b32c2603208?version=1.0) [accessed on 2017-03-15]  
22  
23  
24 14 (19) Lee GK, Wang HH, Liu KQ, *et al.* Determinants of medication adherence to antihypertensive  
25 15 medications among a Chinese population using Morisky Medication Adherence Scale. *PLoS One*  
26 16 2013;8:e62775.  
27  
28  
29 17 (20) Morisky DE, Ang A, Krousel-Wood M, *et al.* Predictive validity of a medication adherence  
30 18 measure in an outpatient setting. *J Clin Hypertens* 2008;10:348-54.  
31  
32 19 (21) Beaton DE, Bombardier C, Guillemin F, *et al.* Guidelines for the process of cross-cultural  
33 20 adaptation of self-report measures. *Spine* 2000;25:3186-91.  
34  
35  
36 21 (22) FMHACA. Hypertension: Standard Treatment Guidelines for General Hospitals, Ethiopia. Third  
37 22 Edition ed.: Food, Medicine and Health Care Administration and Control Authority(FMHACA); 2014.  
38 23 p. 47-53.  
39  
40 24 (23) Gudina EK, Michael Y, Assegid S. Prevalence of hypertension and its risk factors in southwest  
41 25 Ethiopia: a hospital-based cross-sectional survey. *Integr Blood Press Control* 2013;6:111-117.  
42  
43  
44 26 (24) Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment  
45 27 intensification, and control in Western Europe and the United States. *Arch Intern Med* 2007;167:141-  
46 28 7.  
47  
48  
49 29 (25) Wolf-Maier K, Cooper RS, Kramer H, *et al.* Hypertension treatment and control in five European  
50 30 countries, Canada, and the United States. *Hypertension* 2004;43:10-7.  
51  
52  
53 31 (26) Nulu S, Aronow WS, Frishman WH. Hypertension in Sub-Saharan Africa: A Contextual View of  
54 32 Patterns of Disease, Best Management, and Systems Issues. *Cardiol Rev* 2016;24:30-40.  
55  
56  
57 33 (27) SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control.  
58 34 *N Engl J Med* 2015;373:2103-16.  
59  
60

- 1  
2  
3 1 (28) Perkovic V, Rodgers A. Redefining blood-pressure targets - SPRINT starts the marathon. *N Engl J*  
4 2 *Med* 2015;373:2175-78.
- 5  
6 3 (29) Alhawassi TM, Krass I, Pont LG. Hypertension in older persons: A systematic review of national  
7 4 and international treatment guidelines. *J Clin Hypertens* 2015;17:486-92.
- 8  
9 5 (30) Phillips LS, Branch WT, Cook CB, *et al.* Clinical inertia. *Ann Intern Med* 2001;135:825-34.
- 10  
11 6 (31) Moser M. Physician or clinical inertia: what is it? Is it really a problem? And what can be done  
12 7 about it? *J Clin Hypertens* 2009;11:1-4.
- 13  
14 8 (32) Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of  
15 9 resistant hypertension in treated hypertensive populations. *Am J Hypertens* 2015;28:355-61.
- 16  
17 10 (33) Nansseu JR, Noubiap JJ, Mengnjo MK, *et al.* The highly neglected burden of resistant  
18 11 hypertension in Africa: a systematic review and meta-analysis. *BMJ Open* 2016;6:e011452.
- 19  
20 12 (34) Corrao G, Parodi A, Nicotra F, *et al.* Better compliance to antihypertensive medications reduces  
21 13 cardiovascular risk. *J Hypertens* 2011;29:610-8.
- 22  
23 14 (35) Ambaw AD, Alemie GA, Mengesha ZB. Adherence to antihypertensive treatment and associated  
24 15 factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. *BMC*  
25 16 *Public Health* 2012;12:282.
- 26  
27 17 (36) Hareri HA, Abebe M, Asefaw T. Assessments of adherence to hypertension managements and its  
28 18 influencing factors among hypertensive patients attending black lion hospital chronic follow up unit,  
29 19 Addis Ababa, Ethiopia-a cross-sectional study. *International Journal of Pharmaceutical Sciences and*  
30 20 *Research* 2013;4:1086.

31  
32  
33  
34  
35  
36  
37  
38  
3940 **Figure legend**41  
42 23 Figure 1 Flow chart for case inclusion for analysis  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1



194x198mm (300 x 300 DPI)



1  
2  
3 **HYPERTENSION TREATMENT PRACTICES AND ITS DETERMINANTS AMONG AMBULATORY PATIENTS:**

4  
5 **A RETROSPECTIVE COHORT STUDY IN ETHIOPIA**

6  
7  
8  
9 **Supplement Table 1 Determinants of achieving target BP (BP < 140/90) at index visit ambulatory hypertension patients (sensitivity analysis with adherence definition of MMAS  $\geq$  6)**

Variables	Controlled BP		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD), year	58 (13)	56 (15)	#0.99 [0.98; 1.00]	*0.99 [0.98; 1.00]	
Gender (n, %)	Male	219 (67)	109 (33)	Ref	
	Female	331 (60)	220 (40)	#1.34 [1.00; 1.78]	1.12 [0.81; 1.55]
Hospital type (n, %)	Specialized	199 (68)	93 (32)	Ref	
	General	363 (60)	242 (40)	*1.43 [1.06; 1.92]	*1.88 [1.25; 2.81]
<b>Disease characteristics at index visit (n, %)</b>					
Renal disease	No	542 (62)	330 (38)	Reference	
	Yes	20 (80)	5 (20)	#0.41 [0.15; 1.10]	0.60 [0.20; 1.79]
Controlled BP at prior visit	No	424 (68)	199 (32)	*0.37 [0.27; 0.51]	*0.30 [0.21; 0.43]
	Yes	102 (44)	129 (56)	Ref	
<b>Antihypertensive Treatment characteristics</b>					
Duration of therapy, years (mean, SD)		6.2(6.4)	7.4 (8.3)	#1.02 [1.00; 1.04]	*1.04 [1.02; 1.06]
Adherent (MMAS $\geq$ 6) (n, %)	No	237 (63)	140 (37)	Ref	
	Yes	315 (62)	194 (38)	1.04 [0.79; 1.37]	1.14 [0.83; 1.56]
Revisit schedule in months (Mean, SD)		2.2 (1.4)	2.0 (1.2)	*0.89 [0.82 ;0.97]	0.91 [0.82; 1.02]
Beta blockers (n, %)	No	472 (65)	259 (35)	Ref	
	Yes	90 (54)	76 (46)	*1.54 [1.09; 2.16]	1.45 [0.98; 2.15]
Diuretics (n, %)	No	243 (59)	168 (41)	Reference	
	Yes	319 (66)	167 (34)	*0.76 [0.58; 0.99]	*0.68 [0.50; 0.94]

Variables with #p < 0.20 or \*p < 0.05 in the bivariable model were included in this multivariable model (sensitivity analysis).

**Supplement Table 2 Prescribed antihypertensive medication(s) in the study population**

Drug prescribed per case	At Index visit (n <sup>‡</sup> = 887), %	At Prior visit (n <sup>‡</sup> = 882), %
D (Diuretics)	14.3	15.0
C (CCBs)	13.0	13.7
A (ACE inhibitors)	9.9	11.0
B (BBs)	0.8	1.4
D + C	9.4	8.6
D + A	17.0	16.6
C + A	11.5	10.2
A + B	2.6	2.4
C + B	2.4	2.7
D + B	2.0	1.5
D + C + B	1.5	1.1
D + C + A	6.1	6.1
A + C + B	3.7	3.5
D + A + B	2.7	2.5
D + A + B + C	3.2	3.7

CCBs, calcium channel blockers; ACE, Angiotensinogen Converting Enzyme; BBs; Beta Blockers

\*The table did not include rarely used medication categories. These drugs were methyldopa, losartan, hydralazine, and nitrates and in combination with others or as a monotherapy.

**Supplement Table 3 Sensitivity analyses: determinants for controlled hypertension at alternative BP target (BP < 130/80 mm Hg) for patients with DM and/or renal disease, and all other patients BP < 140/90 mm Hg)**

Variables	Controlled BP		Bivariable OR [95% CI]	Multivariable OR [95% CI]	
	No	Yes			
<b>Demographics</b>					
Age (mean, SD)	58 (13)	56 (15)	#0.99 [0.98; 1.00]	0.99 [0.98; 1.00]	
Gender (n, %)	Male	244 (74)	84 (26)	Ref	
	Female	373 (68)	178 (32)	*1.39 [1.02; 1.88]	1.30 [0.87; 1.95]
Smoking (n, %)	No	572 (69)	254 (31)	Ref	
	Yes	45 (79)	12 (21)	#0.60 [0.31; 1.16]	1.05 [0.50; 2.24]
Alcohol use (n, %)	No	354 (72)	140 (28)	Ref	
	Yes	254 (67)	124 (33)	#1.23 [0.92; 1.65]	1.54 [1.07; 2.21]
Marital status (n, %)	Single	207 (67)	104 (33)	Ref	
	Married	406 (72)	161 (28)	#0.79 [0.59; 1.06]	0.82 [0.56; 1.18]
Educational status (n, %)	College/University	123 (72)	47 (28)	Ref	
	Secondary	103 (73)	38 (27)	1.21 [0.83; 1.77]	
	Primary /not formal	381 (68)	176 (32)	0.97 [0.59; 1.59]	
Hospital type (n, %)	Specialized	217 (74)	75 (26)	Ref	
	General	412 (68)	193 (32)	1.36 [0.99; 1.85]	1.17 [0.75; 1.82]
<b>Disease characteristics (n, %)</b>					
Dyslipidemia at index visit	No	583 (69)	257(31)	Ref	
	Yes	46 (81)	11 (19)	#0.54 [0.28; 1.06]	0.47 [0.20; 1.10]
Heart Failure / MI at index visit	No	578 (70)	247 (30)	Ref	
	Yes	51 (71)	21 (29)	0.96 [0.57; 1.64]	
Controlled BP at prior visit	No	501 (77)	151 (23)	*0.25 [0.18; 0.35]	*0.25 [0.17; 0.37]
	Yes	92 (46)	110 (55)	Ref	
<b>Antihypertensive treatment characteristics</b>					
Duration of therapy years (mean, SD)	7.0 (7.3)	5.8 (6.9)	#0.98 [0.96; 1.00]	0.99 [0.97; 1.02]	
Adherence (MMAS-8 $\geq$ 7) (n, %)	No	373 (70)	158 (29)	Ref	
	Yes	246 (69)	109 (31)	1.04 [0.78; 1.40]	
Revisit schedule in months (Mean, SD)	2.4 (2.1)	2.0 (1.2)	*0.88 [0.81; 0.97]	0.94 [0.84; 1.06]	
Therapy at prior visit (n, %)	Monotherapy	240 (66)	123 (34)	Ref	
	Multidrug therapy	378 (73)	143 (27)	*0.74 [0.55; 0.99]	1.02 [0.69; 1.51]
<b>Antihypertensive medications at prior visit</b>					
ACE inhibitors (n, %)	No	274 (68)	129 (32)	Ref	
	Yes	355 (72)	139 (28)	0.83 [0.62; 1.11]	
Beta blockers (n, %)	No	511 (70)	220 (30)	Ref	
	Yes	118 (71)	48 (29)	0.95 [0.65; 1.37]	
Calcium channel blockers (n, %)	No	312 (68)	146 (32)	Ref	
	Yes	317 (72)	122 (28)	#0.82 [0.62; 1.10]	0.88 [0.59; 1.31]
Diuretics (n, %)	No	276 (67)	135 (33)	Ref	
	Yes	353 (73)	133 (27)	#0.77 [0.58; 1.03]	*0.60 [0.40; 0.90]



**Supplement Table 4 Determinants of achieving target BP (BP < 140/90) at index visit in ambulatory hypertensive patients**

Variables	Odds ratio at 95% CI	
	Bivariable estimates	Multivariable estimate
<b>Demographics</b>		
Age [year]		
< 35	Ref	
35-44	0.56 [0.27; 1.18]	0.51 [0.24; 1.10]
45-54	0.51 [0.25; 1.03]	0.53 [0.26; 1.10]
55-64	0.40 [0.20; 0.80]	0.41 [0.20; 0.83]
≥ 65	0.50 [0.25; 0.99]	0.46 [0.22; 0.93]
Gender		
Male	Ref	
Female	*1.34 [1.00; 1.78]	1.15 [0.83; 1.61]
Smoking		
No	Ref	
Yes	0.89 [0.51; 1.56]	
Alcohol use		
No	Ref	
Yes	1.06 [0.81; 1.40]	
Marital status		
Single	Ref	
Married	0.87 [0.66; 1.16]	
Educational status		
College/University	Ref	
Secondary	1.17 [0.74; 1.86]	
Primary /not formal	1.13 [0.79; 1.61]	
Hospital type		
Specialized	Ref	
General	*1.43 [1.06; 1.92]	*2.05 [1.36; 0.09]
<b>Disease characteristics</b>		
Number of cardiometabolic comorbid illnesses	0.86 [0.69; 1.06]	0.84 [0.64; 1.11]
Hypertension severity at prior visit		
Normal BP (systolic BP < 120 and diastolic BP < 80 mm Hg)	Ref	
Pre-hypertensive stage (systolic BP 120-139 or diastolic BP 80-89 mm Hg)	0.83 [0.45; 1.53]	0.80 [0.40; .62]
Stage I hypertension (systolic BP 140-159 or diastolic BP 90-99 mm Hg)	*0.40 [0.21; 0.72]	*0.34 [0.17; .67]
Stage II hypertension (systolic BP ≥ 160 or diastolic BP ≥ 100 mm Hg)	*0.25 [0.14; 0.46]	*0.17 [0.09; .35]
<b>Antihypertensive Treatment characteristics</b>		
Duration of therapy, years (mean, SD)	#1.02 [1.00; 1.04]	*1.04 [1.02; .07]
Adherent (MMAS ≥ 7)		
No	Ref	
Yes	#0.79 [0.60; 1.04]	0.75 [0.54; 1.04]
Revisit schedule in months (Mean, SD)	*0.89 [0.82 ;0.97]	0.93 [0.83; 1.04]
Therapy at prior visit		
Monotherapy	Ref	
Multidrug therapy	0.98 [0.74; 1.29]	
Antihypertensive medications at prior visit		
ACE inhibitors		
No	Ref	
Yes	1.13 [0.86; 1.49]	
Beta blockers		
No	Ref	
Yes	*1.54 [1.09; 2.16]	*1.63 [1.08; .45]
Calcium channel blockers		
No	Ref	
Yes	1.06 [0.81 ;1.39]	
Diuretics		
No	Reference	
Yes	*0.76 [0.58; 0.99]	*0.68 [0.49; 0.94]

Difference with the main analysis (Table 2): Age categorical, prior BP based on severity, and comorbid illness count included.

**Supplement Table 5 Treatment intensification determinants for ambulatory hypertensive patients with uncontrolled BP at index visit**

Variables		Bivariable estimates OR [95% CI]	Multivariable estimate OR [95% CI]
<b>Demographics</b>			
Age, Year	< 35	Ref	
	35-44	1.53 [0.39; 5.99]	1.25 [0.31; 5.02]
	45-54	1.45 [0.39; 5.38]	1.08 [0.28; 4.10]
	55-64	1.95 [0.55; 6.96]	1.20 [0.33; 5.49]
	≥ 65	2.03 [0.57; 7.26]	1.49 [0.41; 2.22]
Gender	Male	Ref	
	Female	#1.35 [0.88; 2.07]	1.40 [0.86; 1.29]
Smoking	No	Ref	
	Yes	0.88 [0.37; 2.07]	
Alcohol use	No	Ref	
	Yes	0.75 [0.49; 1.15]	
Marital status	Single	Ref	
	Married	0.93 [0.60; 1.43]	
Educational status	College/University	Ref	
	Secondary	1.54 [0.80; 2.97]	
	Primary /no formal education	0.95 [0.56; 1.62]	
Hospital type	Specialized	Ref	
	General	#0.68 [0.43; 1.06]	0.78 [0.48 1.29]
<b>Disease characteristics</b>			
Cardiometabolic comorbid illness at current visit		#1.15 [0.86; 1.52]	1.04 [0.74; 1.45]
Hypertension severity at prior visit			
Normal BP (systolic BP < 120 and diastolic BP < 80 mm Hg)		Ref	
Pre-hypertensive stage (systolic BP 120-139 or diastolic BP 80-89)		0.65 [0.20; 2.07]	
Stage-I hypertension (systolic BP 140-159 or diastolic BP 90-99 mm Hg)		0.93 [0.32; 2.68]	
Stage-II hypertension (systolic BP ≥ 160 or diastolic BP ≥ 100 mm Hg)		1.15 [0.40; 3.26]	
<b>Antihypertensive treatment characteristics</b>			
Duration of therapy years (mean SD)		*1.05 [1.02; 1.08]	*1.05 [1.02; 1.08]
Adherence (MMAS ≥ 7)	No	Ref	
	Yes	0.88 [0.58; 1.32]	
Therapy at prior visit	Monotherapy	Ref	
	Multidrug therapy	0.89 [0.59; 1.34]	

Difference with the main analysis (table 3): Age grouped, prior BP based on severity, and comorbid illness count included.

**Supplement Table 6 Determinants of achieving target BP (BP < 140/90) at current visit in ambulatory hypertensive patients (For patient with ≥ 6 months on antihypertensive medication).**

Variables	Odds ratio at 95% CI		
	Bivariable estimates	Multivariable estimate	
<b>Demographics</b>			
Age [year]	#0.99 [0.98; 1.00]	*0.99 [0.98; 1.00]	
Gender	Male	Ref	
	Female	#1.26 [0.93; 1.71]	1.09 [0.78; 1.53]
Smoking	No	Ref	
	Yes	0.92 [0.51; 1.66]	
Alcohol use	No	Ref	
	Yes	1.06 [0.79; 1.42]	
Marital status	Single	Ref	
	Married	0.87 [0.65; 1.18]	
Educational status	College/University	Ref	
	Secondary	1.31 [0.81; 2.13]	
	Primary /not formal	1.14 [0.79; 1.66]	
Hospital type	Specialized	Ref	
	General	*1.48 [1.08; 2.02]	*2.03 [1.34; 3.06]
Diabetes Mellitus	No	Ref	
	Yes		
Dyslipidemia	No	Ref	
	Yes		
Renal disease	No	Ref	
	Yes	0.59 [0.18; 1.99]	
Heart failure/ MI at	No	Ref	
	Yes		
Controlled BP at prior visit	Yes	Ref	
	No		*0.30 [0.21; 0.44]
<b>Antihypertensive Treatment characteristics</b>			
Duration of therapy, years (mean, SD)		#1.02 [1.00; 1.04]	*1.04 [1.01; 1.06]
Adherent (MMAS ≥ 7)	No	Ref	
	Yes	#0.79 [0.58; 1.05]	0.75 [0.55; 1.07]
Revisit schedule in months (Mean, SD)		*0.87 [0.79 ;0.96]	0.92 [0.82; 1.03]
Therapy at prior visit	Monotherapy	Ref	
	Multidrug therapy	1.01 [0.75; 1.36]	
Antihypertensive medications at prior visit			
ACE inhibitors	No	Ref	
	Yes	1.15 [0.86; 1.55]	
Beta blockers	No	Ref	
	Yes	*1.52 [1.06; 2.17]	1.44 [0.96; 2.15]
Calcium channel blockers	No	Ref	
	Yes	1.06 [0.79 ;1.41]	
Diuretics	No	Reference	
	Yes	*0.75 [0.56; 1.00]	*0.68 [0.49; 0.95]

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	12
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	9
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11, also on Figure 1
		(b) Give reasons for non-participation at each stage	11 also on Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12
		(b) Indicate number of participants with missing data for each variable of interest	12
		(c) Summarise follow-up time (eg, average and total amount)	12 (visit schedule)
Outcome data	15*	Report numbers of outcome events or summary measures over time	12 and 13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15 and 17 (Table 2 and 3)
		(b) Report category boundaries when continuous variables were categorized	12 (Table 1)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplement Tables 1-6)
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	18
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-19 and 21-22
Generalisability	21	Discuss the generalisability (external validity) of the study results	22
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).